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Chapter 1
General IntroductionThe central dogma of molecular biology postulates that DNA is converted into RNA in the process of transcription, which in turn is converted into the building blocks of cells, proteins, in the process of translation. Transcription and translation are the main steps of gene expression, i.e. the conversion of genetic information into a functional product. 
During development, multicellular organisms undergo tissue specification and es-tablishment of diverse cellular phenotypes. While all these cells share the same DNA, in order to achieve the functional and phenotypical diversity, each cell type 
“reads” the DNA code differently, which results in a cell-type specific gene expres-
sion profile. The field of epigenetics studies molecular mechanisms that govern the diverse execution of the DNA code, and thus provides a link between the genotype and phenotype. The mechanisms that affect DNA code interpretation include e.g. 
modifications of histones, DNA methylation, and the three-dimensional organization of the genome.
Histone code
Human diploid cells contain approximately 2 meters of DNA, which is ~200,000 times longer than the average diameter of a nucleus (10 mm).  In order to fit in a nu-cleus, the DNA is elaborately packaged by histone proteins that together with the DNA comprise the chromatin. The basic repeating unit of chromatin, the nucleo-some, represents 147 basepairs (bp) of DNA wrapped around a histone octamer, 
comprised of two copies of the four core histones: H3, H4, H2A and H2B (Figure 1). Nucleosomes are further organized into arrays and stacks of arrays connected by 
linker histone H1. Based on the degree of compaction, chromatin is generally divid-ed into “euchromatin” - a permissive and accessible environment, and “heterochro-matin” - an inaccessible environment (1). 
Post-translational modifications (e.g. acetylation, methylation and phosphoryla-
tion) of specific residues of histone tails and core histones form the “histone code”, an additional layer of information that provides instructions for reading the DNA 
code (3,4) (Figure 1). These modifications can change chromatin organization and have an impact on transcription, either by directly altering histone-histone and his-tone-DNA interactions or by recruiting other proteins (1). The enzymes involved 
in the chromatin modification cascade can be generally divided into three broad 
11
General introductioncategories:
(1) “writers”, chromatin modifiers that can introduce post-translational modi-
fications such as histone acetyltransferases (HATs).
(2) “erasers”, enzymes that remove post-translational modifications such as 
histone deacetylases (HDACs).
(3) “readers”, effector proteins that recognize and bind to modified histones and exert chromatin-modifying activity such as bromodomain proteins (BRDs).
Figure 1: Schematic representation of chromatin organization within the nu-
cleus. DNA is wrapped around histone octameres, forming nucleosomes. Nucleosomes 
are further organized into chromatin fiber, where nucleosome arrays are connected 
by linker histones. Chromatin fiber folding represents higher-order organization of 
chromatin. Epigenetic regulation is achieved through e.g. histone tail modification, 
DNA methylation and arrangement of chromatin fiber. Figure adapted from Probst, 
2009(2) with permission of the publisher.
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Lysine acetylation can for instance directly facilitate transcription by weakening the interactions between DNA and histones, leading to a more open DNA conformation (5). On the other hand, the bromodomain protein family recognizes and binds to acetylated histone tails (6,7) and facilitates amongst others transcriptional elonga-tion (8,9). Advancement of next generation sequencing technologies allowed the genome-wide 
mapping of various chromatin modifications. These efforts revealed associations be-tween certain chromatin states and transcriptional activity (Figure 2) (10,11). For 
example, H3K27me3 and H3K9me3 are associated with transcriptional repression, 
while H3K36me3 is associated with transcriptional activation and elongation (12). 
Furthermore, histone modifications display differential binding distribution, e.g. 
H3K4me3 is enriched specifically at gene promoters and H3K4me1 is enriched at 
enhancers (13). Thus, genome-wide analysis of histone modifications can be used to annotate functional elements within the genome (Figure 2). 
Figure 2: Schematic representation of the epigenetic make-up of active and re-
pressed genes and their regulatory elements. 
DNA methylationCytosine methylation (5 methylcytosine, 5mC) is a highly conserved epigenetic 
modification that is deposited directly on the DNA and is generally associated with gene repression. 
13
General introductionThe methylation pattern is established during early embryonic development by de novo DNA methyltransferases DNMT3A, DNMT3B and DNMT3L (14,15), while 
DNMT1 together with UHRF1 are responsible for maintaining the methylation pat-tern during DNA replication (16). In turn, demethylation can occur passively during replication or actively via the enzymatic action of ten-eleven translocation (TET) dioxygenases (17). TET proteins convert methylated 5methylcytosine into 5-hy-droxymethylcytosine via oxidation (18). Subsequent oxidations lead to formation of 5-formylcytosine and 5-carboxylcytosine (19). 5-carboxylsytosine can be excised 
from the DNA by thymine DNA glycosylase (TDG) followed by base excision repair (20). 
In mammalian cells methylation predominantly occurs at cytosines in a CpG dinu-
cleotide context, while non-CpG methylation is rare (17). In the human genome the 
majority of the CpGs are methylated (60-80%) (21). An exception to this are the CpG 
islands (CGIs), high-density clusters of CpGs often associated with gene promoters, 
which are predominantly unmethylated (22). Comparison of methylation profiles 
across a large panel of human cell lines and primary tissues revealed that about 20% 
of CpGs display a dynamic methylation profile (21). These dynamically methylated regions are mostly located distally to promoters and associated with cell-type spe-
cific transcription factor (TF) binding (21), which can create or maintain a low meth-ylation level at regulatory regions (23,24). While some TFs (e.g. CTCF and REST) are able to protect their binding loci from de novo methylation, others (e.g. NRF1) are incapable of maintaining low methylation levels and can be outcompeted by de novo DNA methylases (25).
Transcription factorsTranscription factors (TFs) are regulatory proteins that bind DNA and modu-
late gene expression through repression or activation(26). Genome-wide TF occu-
pancy profiling suggests that over 90% of TF binding sites (TFBS) are located within accessible chromatin regions (27), including transcription start site proximal ele-ments or promoters, and distal regulatory elements or enhancers.The TF recognition sequences on the DNA (motifs) are typically 6 to 12 bp long (26). Considering the large size of eukaryotic genomes together with these rather short recognition sequences for TFs, it is possible that some of the motifs are non-func-tional and appear by chance (28). Indeed, in vivo only a subset of TF motifs is actu-
14
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ally bound by a TF suggesting that additional mechanisms are controlling the speci-
ficity of the binding. Epigenetic make-up and cooperative binding have been shown 
to influence TF occupancy(29,30). Furthermore, sequence context has recently been 
shown to influence TF function, i.e. a TF can act as an activator or repressor depen-dent on the associated co-factors (31).
Figure 3: Establishment of the cell-type specific regulatory landscape: the com-
plex cascade of chromatin remodeling by pioneering TFs, cell-type specific co-activa-
tors and signal-induced TFs.Tight wrapping of the DNA around the histone octamer makes it inaccessible for the 
majority of TFs. However, some TFs, known as pioneers, can bind to previously inac-cessible DNA and via direct nucleosome repositioning or recruitment of chromatin remodeling complexes create a platform for binding of secondary TFs and initiate transcription (1,32). Binding of non-pioneer or “settler” TFs and DNA accessibility directly depends on pioneer binding (33). Activity of pioneering TFs has been shown 
to be crucial for cellular specialization, as it establishes a tissue-specific regulatory landscape (34). For example, classic pioneering factors OCT4, SOX2 and KLF4, that drive cellular reprogramming towards pluripotency, are able to bind to the nucleo-somes and recognize their partial motifs on the compacted DNA in vivo (35). Sim-ilarly, C/EBPa has a pioneering activity during pre-B cell trans-differentiation into macrophages, where it primes previously inaccessible myeloid enhancers (36).
Thus, execution of cell-type specific gene expression programs relies on combinato-
rial action of TFs binding to specific regulatory sequences. This binding represents 
15
General introductionan orchestrated event where pioneering TFs unfold tightly wrapped, inaccessible 
DNA and create binding sites for secondary TFs leading to the activation of specific regulatory elements (Figure 3). 
Transcriptional control of monocyte development, dif-
ferentiation and function
Monocytes are cells circulating in the bloodstream that mediate an inflamma-tory response (37). Monocyte development is a multi-stage differentiation process 
that starts in bone marrow with hematopoietic stem cell (HSC) and through a num-ber of intermediate stages leads to monocytes, which are released into the blood-stream (Figure 4)(38). Each of the differentiation stages is associated with a distinct gene expression and epigenetic landscape, established and maintained by TF net-works (39,40). Transcription factors playing a prominent role in myeloid differenti-ation are amongst others PU.1, C/EBP, IRF8 and RUNX(38). 
Figure 4: Schematic overview of monocyte development and differentiation 
stages. HSC - hematopoietic stem cell, MPP - multipotent progenitors, CMP - common 
myeloid progenitor, GMP - granulocyte-monocyte progenitor, Mo - monocyte, MF - 
macrophage. Circulating monocytes are able to recognize pathogen invasion via interaction be-tween cell-surface expressed pattern recognition receptors (PRRs) and pathogen-as-
sociated molecular patterns (PAMPs) (41). Activated monocytes fight infection by phagocytosis and secretion of cytokines. Furthermore, circulating monocytes are able to migrate to tissue and differentiate to macrophages, which can be further activated(37). The functional response of macrophages is highly diverse and is de-
termined by the tissue microenvironment and the inflammatory stimuli(42-44). This diversity can be illustrated by the well-described polarization states of mac-
rophages, displaying distinct metabolic and chemokine production profiles: (1) the 
classically activated inflammatory (M1) phenotype and (2) the alternatively activat-
ed anti-inflammatory (M2) phenotype (37,45). 
HSC MPP CMP GMP Mo MΦ
Proliferation Differentiation
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Chapter 1The monocyte-to-macrophage differentiation process occurs in the absence of cell division, and, despite of close relation between these cell types, is associated with wide-spread transcriptional and epigenetic reprogramming (46,47). Furthermore, 
exposure of macrophages to different inflammatory stimuli results in a spectrum of different transcriptional responses (44). This high transcriptional plasticity can be explained by sequential TF binding (Figure 3). Binding of pioneering TFs (e.g. PU.1) 
leads to priming of macrophage specific enhancers through nucleosome remodel-
ing and deposition of H3K4me1(48). Binding of tissue-specific TFs to the primed enhancers leads to establishment of different enhancer repertoires dependent on the macrophage environment (43,49). These enhancers can be further accessed by 
various signal-dependent TFs (e.g. AP-1, NF-kB, GR) resulting in a wide spectrum 
of inflammatory responses (48,50) (Figure 3). Furthermore, several recent studies suggest that signal-dependent TFs are capable of de novo enhancer priming upon activation (51,52).
Regulation of inflammatory response by signal-depen-
dent TFs 
The inflammatory reaction is triggered by an interaction between immune cell 
pattern recognition receptors (e.g. TLR, NOD, RIG-I) and pathogen-associated mo-lecular patterns. This interaction through downstream mediators can lead to the 
activation of signal-dependent TFs which, in turn, mediate an inflammatory gene expression program, e.g. by inducing cytokine expression (53). Inducible TFs that 
mediate the inflammatory response include amongst others NF-kB, AP-1 and nu-
clear receptors (54). Here we will focus on two of these TFs: NF-kB, an important 
regulator of the pro-inflammatory response (55), and glucocorticoid receptor (GR), 
which has a prominent role in the anti-inflammatory response (56-58).
The mammalian NF-kB TF family consists of five evolutionary conserved proteins: p65 (RelA), RelB, c-Rel, p50 and p52 (59). All of these factors can bind DNA, while only p65, RelB and c-Rel possess an activation domain, required for positive reg-ulation of transcription (59). In its inactive form, NF-kB resides in the cytoplasm in association with IkB proteins. Its canonical activation pathway starts with rapid degradation of IkBa and release of NF-kB dimers that can translocate to the nucleus and bind to the DNA. Activation of transcription by NF-kB was shown to be depen-
dent on p65 phosphorylation as this modification promotes interaction between 
17
General introductionp65 and histone acetyltransferases CBP/P300 (60). NF-kB TF was shown to have some pioneering activity, but binds predominantly to accessible sites established by lineage-determining factors (52).
Glucocorticoid receptor is a ligand-inducible TF that belongs to the nuclear recep-
tors superfamily. In the absence of ligand, inactive GR resides in the cytoplasm in 
a complex with chaperone proteins and immunophilins (58). Upon induction, GR 
dissociates from this complex and translocates to the nucleus, where it can influ-ence gene expression by direct binding to DNA via glucocorticoid response elements 
(GRE), or indirect binding via cofactors (e.g. AP-1) (61). GR binding sites are mostly distal from promoters and located within accessible chromatin(62,63). Functionally, 
GR can act both as an activator and a repressor(58,64), by recruiting various co-fac-tors, e.g. CBP/P300(65) and NCoR(66). 
The molecular cross-talk between GR and NF-kB TFs is highly complex (67-69) as it 
involves multiple mechanisms, e.g. repression of NF-kB by direct GR binding (70,71), competition for limited cofactors (65) and cooperation of the two TFs (68,72). 
Acute myeloid leukemiaAcute myeloid leukemia (AML) is a hematologic malignancy characterized by 
neoplastic transformation of myeloid progenitor cells. In more than 50% of cases, AML is associated with non-random chromosome translocations(73), which inter-fere with the gene expression program by e.g. regulatory elements repositioning (74) or expression of aberrant oncofusion proteins(75). An oncofusion is a hybrid of two independent genes that recombine, resulting in a malfunctioning protein that contains the DNA binding domain of one, and the effector domain of another protein. 
Different oncofusions are associated with distinct gene expression profiles(76) and cellular differentiation stages (75). They can alter normal gene expression by mis-regulation of the TF activity of the original unfused genes, changing the epigenetic landscape, recruitment of co-regulators, or hijacking of the transcriptional machin-ery (77).  Translocations involving the mixed lineage leukemia (MLL1) gene with over 50 dif-ferent fusion-partners are commonly found in aggressive lymphoid and myeloid 
leukemias(78). MLLs are histone methyltransferases that deposit H3K4me3 on e.g. 
HOX genes (79) and aberrant up-regulation of HOX is a hallmark of MLL-rearranged leukemias(80). MLL-fusions retain the ability to bind to MLL-targets and enhance 
18
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their expression via aberrant elongation(81) and deposition of H3K79me2 (82,83). 
In this thesis
In the nucleus, chromatin is generally highly compacted. However, it can be 
dynamically accessed and modified by TFs and chromatin-associated enzymes, en-abling robust spatiotemporal regulation of transcription. Furthermore, the arrange-ment of chromosomes is not random and provides an extra layer of transcriptional regulation by maintaining proper communication between regulatory elements. In this thesis we aimed to investigate the role of the three-dimensional chromatin 
arrangement in cell-type specific transcription regulation. In Chapter 2 I review the current understanding of chromatin organization dynamics during differentiation and in response to external stimuli. Furthermore, I discuss the importance of the three-dimensional organization of chromatin for transcriptional regulation and how its alterations can lead to disease. In Chapter 3 we assess chromosome conforma-
tion changes mediated by two ligand-induced TFs, glucocorticoid receptor (GR) and nuclear-factor kappa B (NF-kB), in fully differentiated cells. In this chapter we iden-
tified a subset of long-range interactions that dynamically respond to GR and NF-kB activation suggesting that the three-dimensional chromatin landscape in differenti-
ated cells retains a certain degree of flexibility and can be dynamically modulated by 
external stimuli. Here I performed 4C-seq experiments and wrote the manuscript. In Chapter 4 we assess higher-order chromatin organization during terminal myeloid differentiation by focusing on two closely related cell types: monocytes and macro-phages. We show that monocyte-to-macrophage differentiation is associated with 
profound changes of chromatin organization on multiple levels. Here I performed 
the experiments, prepared the figures and wrote the manuscript. In Chapter 5 we in-vestigate the epigenetic and transcriptional landscape of MLL-fusion induced acute 
myeloid leukemia. We find that the MLL-AF9 and -AF4 oncofusions mediate expres-sion of their targets not only via direct binding to promoters, but also by associating 
with enhancers and influencing gene expression through the long-range interaction 
landscape. Here I performed 4C-seq experiments, analyzed the data and prepared 
the figures. In Chapter 6 I summarize and discuss the results presented in this thesis. 
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AbstractThe spatial organization of chromatin in the nucleus is important for proper 
regulation of gene expression. The cell-type specific transcription program is main-ly controlled by distal regulatory elements, which can dynamically engage in long-range interactions with their target genes. These long-range interactions mostly oc-cur within insulated genomic domains and are constrained by global organization of 
the chromatin, providing an extra layer of regulation.  Genetic alterations can lead to disruption of spatial organization and consequently aberrant gene expression. In this review we will discuss the multiple layers of chromatin organization, how this organization changes during differentiation and in response to external stimuli and how its disruption can lead do aberrant gene expression and disease. 
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Higher-order chromatin organizationChromosomes in an interphase nucleus are not randomly positioned, but oc-cupy distinct parts of the nucleus or ‘chromosome territories’ (CTs) (1-3), where gene-poor chromosomes tend to locate at the nuclear periphery and gene-dense chromosomes in the nuclear interior (4). CTs are further compartmentalized, and gene positioning within a CT correlates with its transcriptional activity (Fig1i) (5-8).
Figure 1: Layers of three-dimensional chromatin organization within the nucle-
us. (i) Schematic representation of non-random arrangement of chromosomes within 
an interphase nucleus, with each chromosome occupying its territory. (ii) Zoom-in on 
a part of a chromosome territory: chromatin is further organized in active “A” (green) 
and inactive “B” (yellow) compartments, with “B” compartments being partially asso-
ciated with the nuclear lamina. Compartments are subdivided in topological domains 
(green and yellow circles) (iii) Zoom-in on a transcription factory: distally located ac-
tive genes interact in the nuclear space and reach-out to the factory via long-range 
looping, leading to their simultaneous transcription. (iv) Zoom-in on a topological do-
main: regulatory elements form long-range interactions with their target genes within 
the same domain. Domain boundaries are demarcated by insulator protein CTCF (grey 
circles).Fine mapping of chromosome architecture with molecular techniques provided fur-
ther evidence of chromosome compartmentalization (9). Genome-wide profiling of 
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pair-wise chromosome contacts with HiC revealed that the chromatin is spatially organized into two compartments (“A” and “B”). Regions located in the same com-partment preferentially interact with each other, with transcriptionally active open chromatin being located in the A compartment and inactive closed chromatin in the B compartment (10). A and B compartments are further partitioned into sub-mega-base self-interacting regions or topological domains (TADs), that are conserved be-tween mice and humans (Fig1ii) (11,12). TADs are characterized by a high frequen-cy of intra-domain interactions and a much lower frequency with regions outside of TADs (11). While TADs are stable during differentiation, their organization into A/B 
compartments is dynamic and cell-type specific (13). Chromosome compartmen-
talization has also been observed by profiling genome-wide nuclear lamina (NL) interactions (14) and the replication timing (RT) (15). The inactive, gene-poor “B” compartments correlate to some extent with lamina-associated domains (LADs) and late-replicating domains; and the active, gene-rich “A” compartment with intra-LADs and early-replicating domains (16). TADs, LADs and RT domain boundaries are as-sociated with insulator protein CTCF (11,12,14,15). Interestingly, the replication 
domain boundaries align nearly 100% with TAD boundaries and simultaneously replicating TADs comprise RT domains (16). Reorganization of RT domains during differentiation correlates with changes of radial gene positioning within the nucleus (15), and changes in nuclear architecture on TAD level are affecting RT domain for-mation, thus further supporting the role of nuclear organization in the replication program (17). Furthermore, TADs are concordant with polytene chromosome bands in Drosophila, implying a direct relation between TADs and chromatin compaction (18). All together these observations suggest that TADs act as units or building blocks of 
chromatin organization (19), reflecting local chromatin compaction and gene activi-ty state. Proper establishment and maintenance of spatial organization is crucial for normal regulation and its alterations has been associated with multiple diseases, e.g. laminopathies and cancer(20).
Spatial clustering of co-regulated genesIn the nuclear space, upon activation, distally located genes can organize into transcription units or “transcription factories”. These transcription factories are 
packed with active RNA polymerases and transcription factors (TFs) (21). In HeLa 
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Dynamic chromatin organization: role in development and diseasecells only a couple of thousand transcription factories were detected per nucleus (22). This, in combination with the assumption that many more genes than that are being transcribed at a given time, led to the hypothesis that multiple genes can be si-multaneously transcribed in a factory. These genes can reach the factory via looping mechanisms (Fig1iii) (22) (21,23). 
Fluorescent in situ hybridization (FISH) and chromosome conformation capture (3C) analyses validated this hypothesis on several erythroid genes separated by megabases in the linear genome. It was demonstrated that these genes often co-lo-calize in nuclear space and share a transcription factory (24) (25). Furthermore, the association of genes with transcription factories can be dynamic, with recruitment of active genes and temporary exclusion of inactive genes (25). The dynamic repo-sitioning of genes in nuclear space, associated with change in expression, was also demonstrated for the Hoxb locus where the induction of Hoxb9 and Hoxb11 genes correlated with their movement towards the outside of the chromosomal territo-ry and into the interior of the nucleus (7). A similar observation was made for the pluripotency genes OCT4 and NANOG in human embryonic stem cells (hESCs) (26).
Genes regulated by the same TFs tend to co-localize, suggesting further specializa-tion of transcription factories, e.g. Klf1, NF-kB and pluripotency factor networks (24,27,28). Similarly, loci associated with Polycomb proteins and the repressive 
chromatin modification H3K27me3 tend to cluster together (29-31). Thus, genes 
with similar TF binding profiles and expression status separated by megabases in 
the linear genome tend to interact in nuclear space. Artificial tethering of TFs via the lac integration cassette has further corroborated this observation. Wijchers and 
colleagues demonstrated that ectopic recruitment of NANOG leads to formation of 
ectopic contacts with other NANOG-occupied regions, while recruitment of EZH2 
enforces contacts with H3K27me3 marked loci (32). To summarize, spatial clustering of linearly distal loci in nuclear space is important for proper gene expression regulation. Next to that, as spatial clustering is to some extent dependent on local protein composition, it suggests an importance of bio-chemical compatibility between loci for long-range regulation. Furthermore, global chromatin organization constrains a locus in roaming the nucleus, which could po-tentially explain the different susceptibility of a locus to spatial repositioning (32).
Long-range interactions within the TADs
30
Chapter 2Distal regulatory elements such as enhancers function largely in a cell-type 
specific manner, are often established by pioneering lineage-specific or signal-de-
pendent TFs and drive cell-type specific gene expression programs (33-39). Further-more, enhancers are able to function over large linear distances and regulate their targets via looping mechanisms (Fig1iv) (40-43). These long-range interactions are naturally constrained by TAD borders (44,45) Accordingly, deletion of CTCF binding sites at TAD boundaries (46,47) or changing their orientation (48) leads to ectopic interaction formation and aberrant gene expression, indicating the importance of the 3D genome in maintaining proper enhancer-promoter communication and reg-ulation of transcription (49,50).Many efforts have been directed at linking regulatory elements to their target genes. 
However, a simple assignment of enhancer to closest gene was shown to be inaccu-
rate (51-54). The development of 3C and derivative methods has significantly im-proved enhancer-target assignment (51-53).  The original 3C technique was report-
ed by Job Dekker and colleagues in 2002 ((55). 3C is based on fixation of the 3D DNA structures with formaldehyde, fragmentation of DNA by restriction digestion and ligation of proximal DNA ends. Combination of the 3C technique with high-through-
put sequencing resulted in a variety of methods including 4C (56), 5C (57), Hi-C 
(10), ChIA-PET (58), Capture-C (59) and Capture Hi-C (60).One of the classical examples of long-range regulation of gene expression uncovered with 3C-based technologies is the a-globin locus. The enhancer element (or locus control region (LCR)) of a-globin genes regulates its targets by direct looping to the promoters in fetal liver, where a-globin genes are expressed, but not in fetal brain, where these genes are silent (61). Furthermore, the conformation of the a-globin locus changes during erythroid differentiation. The activated a-globin genes are found in close proximity to the LCR, forming an active chromatin hub in erythroid cells. This conformation is not evident in erythroid progenitor cells, where a-globin 
genes are silent (62). LCR-promoter interaction requires the presence of the GATA1 
TF and its co-factor Ldb1 (63). In GATA null erythroblasts the LCR-promoter loop is abolished and the a-globin gene is transcriptionally inactive. However, artificial tethering of Ldb1 to the a-globin promoter with zinc-finger nucleases is enough to induce the loop formation between promoter and LCR and subsequent activation of the a-globin gene (64,65). Further utilization of 3C-based methods in numerous cell types under various con-ditions has led to the development of two complementary models for the establish-
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Dynamic chromatin organization: role in development and diseasement and maintenance of long-range interactions (Fig2): (1) instructive model or 
de novo formation of long-range interactions, where lineage-specific TFs establish a new interaction landscape, which affects the expression of their target genes, and (2) pre-established or permissive model, where the long range-interaction landscape is 
preformed and poised for transcription which can be triggered by lineage-specific TFs (66). 
Figure 2: Instructive and permissive models of long-range interaction formation. 
Instructive model: de novo formation of a long-range interactions by a lineage-specif-
ic or signal-dependent transcription factor (red octagon). (A) Before TF recruitment, 
the regulatory element does not interact with the target gene and the gene is not ex-
pressed. (C) TF recruitment leads to formation of the long-range interaction and gene 
activation. Permissive model: the long-range interaction landscape is established prior 
to TF recruitment. (B) The target gene already interacts with its regulatory element in 
the absence of an activating TF. (C) Upon recruitment to the pre-established loop the 
TF triggers transcription of its target gene.
Interaction landscape in development and differentia-
tion
The 5C-interaction profiling of developmentally regulated loci in mouse em-
bryonic stem cells (mESCs) and neural progenitor cells (NPCs) identified a large 
fraction of cell-type specific long-range interactions on a sub-TAD level. While the constant architectural interactions were found to be associated with CTCF and co-
hesin, the cell specific interactions were enriched for mediator and cohesin. These dynamic interactions correlated with dynamic cohesin binding and cell-type specif-ic enhancer activity(67). The comparison of RNA Pol II ChIA-PET interaction pro-
files in mESCs and B-lymphocytes revealed that differentially expressed genes are 
found in close spatial proximity to cell-specific enhancers. Interestingly, the authors 
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have also identified a group of genes, expressed in both cell types, which switch the enhancer landscape. Authors conclude that such enhancer switching is largely 
controlled by lineage-specific TFs (68). Similarly, promoter interactomes in mESCs and fetal liver cells have also suggested extensive rewiring of enhancer-promoter contacts (69). Furthermore, during hESCs differentiation TAD boundaries remain largely unchanged between the lineages, however changes in chromatin structure occur within TADs with an orchestrated increase or decrease of interactions across the entire domain in a cell type (13). 
Several studies have demonstrated that long-range interaction profiles of plurip-otency-associated genes Pou5f1 and Nanog change upon differentiation of mESCs 
cells to embryonic fibroblasts (mEF). Moreover, their interaction profiles in mEF-de-
rived induced pluripotent stem cells (iPSCs) highly resemble the mESCs profiles (70-72). On a global level, somatic reprogramming has been recently shown to induce widespread changes in chromatin organization, with disruption of somatic found-
er-lineage specific loops and de novo establishment of ESC-specific chromatin orga-nization and long-range interactions (73). Interestingly, early passage iPSCs derived from different somatic cells can still be distinguished based on their global chroma-
tin organization. However, these differences do not correspond to founder-specific 
chromatin domains and are proposed to be acquired specifically during reprogram-
ming in a cell-of-origin specific manner (73).The X-chromosome inactivation during mammalian development provides a unique model for studying the interplay of chromatin topology and gene expression, as one of the chromosomes acquires a repressive chromatin structure (Xi), leading to silencing of most of the genes, while another X-chromosome remains active (Xa) 
(74,75). By high resolution allele-specific 4C profiling of several X-linked genes, it was demonstrated that Xa and Xi indeed have a very different chromatin topology. The silent Xi-located alleles appeared to have a random contact distribution, while 
Xa-located alleles showed a localized interaction pattern (76). However, the global TAD organization remains present on the Xi (12). Interestingly, genes that escape X-inactivation and remain active on Xi are associated with the same TADs, suggest-ing that TADs rather than individual genes coordinately escape silencing (77).Thus, while global TAD organization and architectural interactions remain constant during differentiation, interactions are re-organized on the sub-TAD level. For some loci changes involve de novo formation or loss of long-range interactions, while for others the interaction landscape is rather static and changes in gene expression are 
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Interaction remodeling in response to external stimuliThe long-range interaction landscape of differentiated cells has been exten-sively studied in the context of signal-dependent transcription. The ability of cells to react to a variety of extra- and intra-cellular stimuli relies on signal-dependent TFs, e.g. nuclear hormone receptors and NF-kB family members (36,78). The dynamic regulation of long-range interactions in response to nuclear receptor activation in differentiated cells has been previously reported for estrogen receptor (ER), retinoid X receptor (RXR), progesterone receptor (PR), and glucocorticoid re-
ceptor (GR) (54,79-82). The ER-mediated long-range interactome of estrogen-treat-ed MCF-7 cells indicated the presence of extensive long-range interaction networks 
between ER binding sites. Genes involved in long-range ER-mediated interactions were up regulated by estrogen treatment. In addition, the authors provided exam-ples of coordinated expression of multiple genes sharing this network, as opposed to genes that are not directly involved in ER-mediated interactions (58). In a recent report, the impact of ligand-activated PR on the long-range interactome was as-
sessed by genome-wide Hi-C profiling combined with three-dimensional modeling. The results indicated that TAD structures remain largely unchanged upon PR induc-
tion. However, hormone stimulation induced long-range interaction changes at the intra-TAD level, which correlated with a coordinated change in chromatin state and gene expression (81).  A contrasting view was obtained by studying the long-range organization of the Lcn2 
locus in response to the GR-activating hormone dexamethasone (Dex). GR induction is known to highly activate the Lcn2 gene (83). In order to assess the contribution of long-range chromatin interactions to gene activation, the authors generated 4C 
profiles for this locus before and after Dex treatment. The authors found that the 
transcriptional reprogramming in response to GR does not alter the pre-established interaction landscape (84). Furthermore, it was reported that genes with differential 
response to GR (activation/repression) co-localize in nuclear space (84), contradict-ing the coordinated gene regulation hypothesis (24,58,81).Another signal-induced TF, NF-kB, mediates the inflammatory program in response 
to a variety of extra- and intracellular stimuli, e.g. pro-inflammatory cytokine tumor necrosis factor alpha (TNFa) (85-87). The ability of TNFa to affect gene expression 
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Chapter 2via NF-kB-mediated long-range interactions was previously reported for the MCP-1 gene and its enhancer (88). In another report, the authors employed 4C and ChIA-PET techniques to investigate the interactome changes in human primary endothe-lial cells in response to TNFa. It was demonstrated that upon stimulation, TNFa responsive genes and their nascent RNA transcripts co-localize in nuclear space. The authors further report co-localization of nuclear-translocated NF-kB foci with these nascent transcripts, suggesting that TNFa-responsive genes are co-transcribed in the ‘NF-kB’ factories (28). Furthermore, co-induction of GR and NF-kB was shown to be associated with long-range interaction remodeling at a subset of binding sites 
(54). Genome-wide HiC profiling of fibroblasts in response to TNFa treatment in-dicated that genes sharing the same enhancer set tend to respond similarly to the treatment, thus providing further evidence for coordinated regulation (89). The au-thors found that TAD-structures remain unchanged after treatment, in agreement with the study on progesterone receptor activation (81). Interestingly, the authors did not observe changes in long-range interactions on the sub-TAD level. Further-more, it was demonstrated that treatment-activated enhancers are engaged in long-range interactions with their target genes prior to the treatment, indicating that in-teraction landscape is pre-established and poised for transcriptional activation (89).
Overall these findings suggest that signal-dependent transcriptional activation is mainly achieved within pre-established chromatin organization (84,89) while a sub-set of TADs (81) and individual loci (28,54) display dynamic changes in long-range organization.
Chromatin topology and diseaseThe majority of disease-associated single nucleotide polymorphisms (SNPs) 
identified by genome-wide association studies (GWAS) are located within noncod-ing sequence, or more precisely, are enriched within DNase I hypersensitive sites 
(DHSs)(90), suggesting a role in gene regulation. Many recent studies employed 3C-based methods to link SNPs in non-coding regulatory elements to their target 
genes(60,91,92). For example, GWAS identified several obesity and type 2 diabetes associated SNPs in introns of the FTO gene. However, expression quantitative trait locus (eQTL) studies have not detected any link between these SNPs and expression of the FTO gene. Based on 4C profiling of the locus, it was shown that intronic SNPs of the FTO gene are associated not with FTO, but with the IRX3 gene and regulate its 
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is functionally linked to GWAS-identified SNPs(91). In another recent report the au-thors demonstrated how the combination of 3C-based assays with DNA accessibility and footprints mapping by DNaseI-seq could provide insights into SNP-dependent deregulation of gene expression, with e.g. the Pnpo gene. A distal enhancer of the 
Pnpo gene was identified by Capture-C profiling. With deep DNase-seq data, au-
thors identified footprints of Gata1 and Scl TFs at this enhancer. In three out of eight 
profiled mouse strains, the DNase I site as well as the underlying footprints at this enhancer, and the expression of the Pnpo gene were lost. Interestingly, these three 
strains share SNPs at this enhancer that are not present in the other five strains, suggesting that these SNPs affect binding of TFs to this regulatory element(59). 
However, the direct effect of these SNPs on the long-range enhancer-promoter inter-
action remains to be investigated. Several locus-specific studies have demonstrated 
an effective change of long-range interactions by SNPs(92,93). However, globally, it remains unclear whether SNPs at regulatory elements affect target gene expression by altering the long-range interaction landscape, or rather act within a pre-estab-lished landscape by interfering with TFs binding, i.e. altering established or creating a new TF binding site.Chromosomal translocations are implicated in many types of cancers and can af-fect gene expression and long-range interactions by repositioning of regulatory el-ements(94,95). One of such cases was reported for acute myeloid leukemia (AML) with inv(3)/ t(3;3). This AML subtype is linked to aberrant up regulation of the 
EVI1 gene. Here, authors demonstrated that inversion at this locus repositions an endogenous GATA2 enhancer to the EVI1 gene, leading to aberrant EVI1 activation and down regulation of GATA2(95). Similar mechanisms of aberrant over-expression have been suggested for the MYC gene in multiple myeloma and GFI1 and GFI1B in medulloblastoma(94,96). Furthermore, disruption of TAD borders was also shown to permit ectopic enhancer action and deregulation of associated genes. For exam-ple, structural variations in TAD spanning the WNT6/IHH/EPHA4/PAX3 locus are as-sociated with an aberrant long-range interaction landscape and cause various limb malformations(46). Thus, as evident by ectopic enhancer activity in multiple rear-ranged cancers, TADs provide a necessary layer of regulation, organizing and main-taining proper enhancer-promoter communication, and eventually gene expression.
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Future directionsWith the fast advancement of 3C-based methods it is now possible to re-ad-
dress the question of the role of chromatin organization in the cell-specific gene expression program. As the majority of disease-associated SNPs are located in non-coding elements, 3C based methods can be used to accurately assign these SNPs 
to their targets. This will require a comprehensive high-resolution profiling of the chromatin interactome at different developmental stages or in relation to various diseases. Combination of target enrichment systems with 3C techniques shows a good promise in high-resolution interaction detection for multiple loci of interest with reasonable sequencing costs(59,60). 
However, the existing 3C-methods do not assess the functionality of detected interac-tions. A combination of interactome studies with functional assessment of enhancer capacity is therefore needed. The recently developed STARR-seq(97) technique al-
low large-scale de novo enhancer identification based on their functional activity. This technique can be used to identify potentially disease-causing SNPs that inter-fere with enhancer activity. Furthermore, genetic interference with 3D chromatin organization(46), such as deletion or insertion of new TAD boundaries can further our understanding of the functional relation between global chromatin organization and long-range regulation of individual loci. 
Overall, the current status of the field now permits answering the questions of how 
enhancers find their target and what role the global chromatin organization plays in 
the arrangement of long-range contacts and cell-type specific gene expression. This will lead to a better understanding of how this arrangement is established during development and can be disturbed in disease.
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Chapter 3
AbstractThe impact of signal dependent transcription factors, such as glucocorticoid re-
ceptor (GR) and NFκB on the three-dimensional organization of chromatin remains a topic of discussion. The possible scenarios range from remodeling of higher order chromatin architecture by activated transcription factors to recruitment of activated transcription factors to pre-established long-range interactions.Using 4C-seq and high-resolution ChIA-PET analysis of P300 we observed agonist-in-duced changes in long-range chromatin interactions, and uncovered interconnected enhancer-enhancer hubs spanning up to one megabase. The vast majority of acti-
vated GR and NFκB appears to join pre-existing P300 enhancer hubs without affect-ing the chromatin conformation. In contrast, binding of the activated transcription factors to loci with their consensus response elements leads to increased formation 
of an active epigenetic state of enhancers and a significant increase in long-range in-teractions within pre-existing enhancer networks. De novo enhancers or ligand-re-sponsive enhancer hubs preferentially interact with ligand-induced genes.We demonstrate that, at a subset of genomic loci, ligand-mediated induction leads to active enhancer formation and an increase in long-range interactions, facilitat-
ing efficient regulation of target genes. Therefore, our data suggest an active role of signal dependent transcription factors in chromatin and long-range interaction remodeling.
47
Glucocorticoid receptor and nuclear factor kappa-b affect 3D chromatin organization
BackgroundMechanisms of transcriptional response mediated by signal dependent tran-scription factors (inducible TFs) are not well understood at the level of chromatin topology.  Recent genome wide studies have revealed that the majority of TF binding 
sites (up to 90%) are distal to promoters and located in intragenic and intergenic 
regions (1-9). These studies collectively revealed cell-type-specific constellations of distal regulatory regions that change during differentiation and development in a highly ordered fashion, whereby some distal regulatory regions are being set up de novo and others are decommissioned. This implies that at least some lineage-spe-
cific and/or signal dependent TFs effectively open the chromatin structure and pre-pare the chromatin for subsequent binding of other TFs. A simplistic model of how such plasticity can be achieved is that long-range interactions among and between enhancers and promoters are dynamically established or disrupted. Many recent studies have purported an active or ‘instructive’ role of inducible TFs in mediating 
long-range chromatin contacts for efficient regulation of target genes(10-14). The orchestrated long-range interaction changes have also been reported in embryonic stem cells (ESC) and ESC-derived lineages (15) on topological domain (TAD) level. In contrast, other studies suggest a static or ‘permissive’ model in which inducible TFs passively join pre-existing interaction networks of regulatory elements with-out affecting the organization of long-range interactions (14,16,17). The HoxD locus serves as an example of pre-formed long-range interactions (18). Interestingly, in another report focusing on HoxD locus, the authors directly compared the interac-
tion profiles obtained by 3C-based methods and fluorescent in situ hybridization. 
The authors conclude that interactions identified by 3C-based methods at such high-resolution do not always represent true proximal ligations, but may be a con-sequence of indirect crosslinking (19). Discrepancies between studies on inducible TF-mediated long-range chromatin contacts may be due to differences in resolution and the methodology or to the use of asynchronous cells. 
Glucocorticoid receptor (GR) is a ligand inducible transcription factor that belongs 
to the nuclear receptor superfamily (20). Hormone binding dissociates the GR-con-
taining cytoplasmic complex, GR then translocates to the nucleus where it binds to 
chromatin to regulate target gene activity. Nuclear factor kappa-b (NFκB) is a het-erodimeric TF that regulates various biological processes such as cell growth, de-
velopment and inflammatory response. In response to inflammatory stimuli such 
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as the pro-inflammatory cytokine tumor necrosis factor alpha (TNFα), NFκB dis-sociates from an inhibitory cytoplasmic complex, translocates to the nucleus and 
subsequently regulates its target genes (21-25). Co-activated GR and NFκB share a large proportion of genomic regulatory elements and co-regulate many genes in a 
mutual antagonistic or synergistic manner (7,26-29). The majority of GR and p65 (a 
major NFκB subunit) binding events occur at genomic loci that exhibit pre-existing 
enhancer signatures. In this scenario, TFs other than GR and NFκB have established and maintain an open chromatin conformation facilitating binding or recruitment of 
GR and p65 to their binding sites (30-32). At a minority of GR and p65 binding sites 
(~10%), the activated TFs establish de novo enhancer-like loci (5,33,34). 
To gain insight in how GR and NFκB regulate their target gene repertoire from distal 
binding sites, we mapped the chromatin interactions before and after GR and NFκB 
activation by generating high-resolution chromatin interaction profiles using the ChIA-PET method (35,36). We used antibodies against enhancer-associated P300 
and against RNA-Polymerase II (POLII). P300 is a co-factor shared by GR and NFκB and its genomic occupancy in general is considered a hallmark of active enhancers (37-40). We scrutinized the local chromatin interaction networks at genomic loci that are de novo established and compared them to those of pre-existing loci. We extended our analysis using high-resolution 4C technology on a subset of genom-ic viewpoints harboring de novo programmed regulatory elements. Collectively, our comprehensive analyses reveal a role of signal dependent TF induced dynamic changes in chromatin regulatory networks and its impact on gene regulation.
Results
P300 is recruited to latent distal binding sites by ligand ac-
tivated GR and/or NFκB 
To gain insight into the impact of glucocorticoid receptor (GR) activation on 
the chromatin state and 3D organization, we first performed chromatin immu-
noprecipitation followed by deep sequencing (ChIP-seq) for GR, P300, epigenetic 
marks (H3K27ac, H3K4me3 and H3K4me1) and DNase I accessibility analysis. Li-
gand-activated GR binds to several thousand genomic loci (5,7,8,41) of which more 
than 90% (7679/8303) are located distally (> 5kb) from transcription start sites in 
HeLa cells (Supplementary Fig. 1A). The vast majority (6760/7679) of these distal 
binding sites (DBS) are DNase I accessible, bound by P300, and marked with H3K-
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27ac and H3K4me1 prior to hormone stimulation (Fig. 1A-C). We refer to these as 
‘pre-existing’ P300 sites. Importantly, a subset of GR distal binding sites (919/7679) displays the hallmarks of poised enhancers prior to ligand treatment, being large-
ly inaccessible to DNase I, lowly marked with H3K4me1, and not marked with 
H3K27ac and P300. Interestingly, to these epigenetically dormant loci, P300 is ro-
bustly recruited upon GR induction (‘induced’ P300 sites; Fig. 1A-C). At a smaller 
subset (529/6760) of GR DBS, P300 occupancy is moderately reduced upon hor-mone treatment (data not shown). Next, we analyzed the pre-existing and induced P300 DBS for TF motifs (7). As expected, ligand induced P300 DBS are highly en-
riched for Glucocorticoid Response Elements (GREs), whereas AP1 is the most prev-alent motif detected at pre-existing P300 sites (Fig. 1D). Our observations together 
with published data (John et al 2011) suggest that at the induced P300 DBS that are 
pre-marked with H3K4me1, GR binds directly to consensus GREs and recruits P300 to set up enhancer-like elements. P65 is also predominantly bound at distal genomic loci (11454/12546) (Supple-mentary Fig. 2A), of which the majority (10453/11454) are occupied by P300 prior 
to TNFα stimulation (pre-existing P300 sites). At a subset of p65 DBS (1001/11454), 
P300 is detectable only upon TNFα stimulation (Supplementary Fig. 2B,C). TNFα-in-
duced P300 DBS are enriched for the NFκB response element (NFκB-RE) (Supple-
mentary Fig. 2D). Furthermore, induced P300 DBS are barely or not marked by H3K-
27ac are inaccessible to DNase I, yet display readily detectable levels of H3K4me1 
prior to TNFα induction and p65 binding (Supplementary Fig. 2E). In line with a 
recent study in mouse macrophages (34), we presume that TNFα induction activates poised or latent enhancers. We also observed pre-existing P300 binding at many 
sites (~25,000) that are not significantly co-occupied by GR or p65 (Supplementary Fig. 3A,B). These sites likely have a regulatory role in association with other TFs.
As GR and p65 share a large number of regulatory elements (~30%) and co-regulate 
many genes, we performed a similar analysis upon co-activation of GR and p65. We 
detected all the induced P300 DBS that were uncovered upon single activation of GR 
or p65. An additional subset of inducible P300 sites (~700) was unveiled only upon 
co-stimulation, displaying significantly increased DNase I accessibility and H3K27ac, 
and a marginal increase in H3K4me1 (Supplementary Fig. 4-5, Supplementary text). 
Taken together, GR and p65 mostly join pre-existing enhancer-like P300 DBSs that are set up by other TFs such as AP1. At a subset of latent genomic locations that 
is marked with low levels of H3K4me1, GR and/or NFκB binding induces DNA 
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Figure 1: Activated GR recruit P300 to epigenomically latent genomic regions. 
(A) Color profile depicting the GR and P300 signal at all GR bound regions with either 
constitutive or ligand (TA) induced P300 occupancy. (B) Example screenshot depicting 
the TA induced P300 DBS (dotted box) and constitutive P300 DBS. (C) Basal (untreated 
cells) H3K27ac, DHS and H3K4me1 signal at all GR induced and constitutive P300 DBS. 
(D) Motif occurrence at all GR bound DBS presented as a function of TA-dependent 
P300 recruitment (x-axis).
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accessibility, recruitment of P300, and H3K27ac deposition. As the induced P300 sites are highly enriched for their respective consensus response elements, it ap-
pears that recruitment of GR and NFκB to their respective cis-acting elements can 
initiate the formation of an active enhancer configuration, in line with recent studies (5,33,34).
ChIA-PET reveals P300 enhancer interaction networksNext we focused on long-range chromatin contacts associated with P300 DBS. We performed chromatin interaction analyses on co-stimulated cells as that uncov-ers the largest number of induced P300 DBS (2881), and contrasted them to ve-hicle treatment. We performed ChIA-PET, an antibody based method to map the genome-wide chromatin interactions at high resolution (35,36,42). We mapped the chromatin interactions using P300 and RNA Polymerase II (POLII) antibodies. Sequencing of the P300 ChIA-PET libraries yielded 36.7 and 18.2 million uniquely mapped paired-end reads (PETs) for vehicle and co-stimulated samples, respective-
ly. Among these, 1.4 and 1.2 million reads were self-ligation PETs (defined as ligation endpoints or anchors less than 5kb apart) accounting for 15148 and 16366 putative P300 binding sites in vehicle and co-treated libraries, respectively (Supplementary 
Table 1). The vast majority (>90%) of these self-ligation PETs co-localize with the 
P300 binding sites identified by ChIP-Seq (Supplementary Fig. 6A). ChIP-Seq bind-ing sites with low signal strength were not detected as binding sites in ChIA-PET data sets (Supplementary Fig. 6B). Therefore, we used ChIP-Seq binding sites (iden-
tified from ~20 million unique reads) as anchors to identify high confidence chro-matin contacts. Ligation PETs that have their anchors between 5 and 1000 kb from 
each other and co-localize with high confidence P300 ChIP-seq binding sites were 
defined as long range interactions. We identified 2363 and 5429 intra-chromosomal interactions using the P300 antibody in vehicle and co-stimulated cells, respectively. Using a similar approach, a large number of intra-chromosomal interactions were detected in a ChIA-PET analysis using a POLII antibody (Supplementary Table 2). P300 and POLII ChIP-Seq binding sites that were involved in chromatin interactions were of higher signal strength compared to those not detected in chromatin interac-tions (Supplementary Fig. 6C). The majority of P300-associated long-range interactions occur between distal reg-
ulatory elements (DBS, ~60 %), whereas about 20% occur between promoters and 
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Figure 2: P300 ChIA-PET interaction profile shows an enhancer-centered inter-
action pattern in contrast to promoter centered POLII interactome. (A) Propor-
tion of DBS-promoter, promoter-promoter and DBS-DBS interactions identified by 
P300 ChIA-PET in vehicle (upper panel) and TA+TNFα (lower panel) treated cells. (B) 
Proportion of DBS-promoter, promoter-promoter and DBS-DBS interactions identified 
by POLII ChIA-PET in vehicle (upper panel) and TA+TNFα (lower panel) treated cells. 
(C) Venn diagram depicting the extent of overlap between P300 interaction sub-do-
mains and POLII interaction subdomains (upper panel). Histogram depicting the per-
centage of P300 and POLII shared anchors in ‘P300 & POLII’ interaction sub-domains 
(lower panel). (D) Example screenshots of P300 rich, P300 & POLII rich and POLII rich 
interaction sub-domains depicting the ChIP-Seq and ChIA-PET interaction data. (E) 
Distribution of GR (left panel) and p65 (right panel) binding sites in P300 rich, P300 & 
POLII rich and POLII rich interaction subdomains.DBSs (Fig. 2A). In contrast to the P300 interactome, POLII-associated interactions 
are found predominantly between promoters (64%) and only 19% involve DBS-pro-
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moter interactions (Fig. 2B). Visual inspection suggests that identified chromatin interactions occur frequently between a multitude of P300 DBSs that aggregate into interaction sub-domains (Supplementary Fig. 6D) similar to replication or topo-
logical domains (TAD) (43,44). Indeed, more than 95% of all P300 and POLII long-
range interactions were confined to such domains as defined by DNA replication 
timing in HeLaS3 cells (44,45) (Supplementary Fig. 6E). Whereas the average TAD 
length is ~1.7 Mb, the average width of P300 and POLII sub-domains are 118 kb and 96 kb, respectively. Direct comparison of individual P300 and POLII interaction 
domains reveals that two fifths (39.6 %) overlap, whereas the remainder appears to involve only P300 or POLII (Fig. 2C, upper panel). The degree of P300 and POLII anchor overlap in P300 and POLII shared interaction domains varies, with most of 
the sub-domains sharing less than 50% of anchors (Fig. 2C, lower panel). Represen-
tative examples of ‘P300 rich’ (left panel), ‘P300 & POLII’ (middle panel) and ‘POLII rich’ (right panel) interaction sub-domains are shown (Fig. 2D).
As GR and p65 preponderantly bind to putative enhancers that are marked with 
P300, it would be expected for GR and p65- binding sites to be enriched within the 
P300 ChIA-PET interaction network. Indeed, about 60% of GR and 50% of p65 bind-ing sites are located within P300 centric interaction sub-domains (P300 rich, P300 
& POLII). POLII rich promoter-promoter networks are largely devoid of GR and p65 binding events (Fig. 2D,E). 
Ligand treatment enhances long-range interactions at in-
duced P300 distal binding sites Next we set out to investigate whether pre-existing and induced P300 sites participate equally in long-range chromatin interactions. Upon ligand activation we 
observe a significant gain of DNaseI accessibility and active chromatin marks at in-duced P300 DBS. We reason that these sites might have an increased interaction upon ligand activation. To validate the P300 mediated long-range interactions and to gain insight into their frequency, we selected 4C viewpoints in eight different P300 interaction sub-do-mains that encompass 58 different genomic loci (anchors) in our ChIA-PET analy-sis. 4C-Seq libraries from at least two independent biological replicas per viewpoint were sequenced to obtain more than 2 million high quality, uniquely aligned reads (Fig. 3 and Supplementary Fig. 7,8,9). This sequencing depth is regarded adequate 
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Chapter 3to map all ligation events within the viewpoint (46). In the ZBTB16/NNMT locus (Fig. 3A), transcription of the NNMT gene is induced by co-stimulation. This locus contains one ligand induced P300 binding site that 
also gains H3K27ac and DNase I accessibility (see also Fig. 1B) and three pre-ex-isting P300 sites. Using one of the pre-existing P300 sites as the viewpoint in 4C experiments (arrow) we detected its interaction with other pre-existing P300 sites. Upon ligand activation, we observed the formation of novel interactions involving the ligand induced P300 DBS as well as a general increase in the interaction signal at pre-existing sites. In ChIA-PET, we only detect interactions between all the en-hancers only upon ligand induction.The KLF6 locus encompasses multiple constitutive and four induced P300 binding sites (Fig. 3B). Upon stimulation, transcription of the KLF6 gene is highly induced 
and multiple enhancers gain P300, H3K27ac, and DNase I accessibility. A GR-induced DBS was used as the viewpoint for 4C (arrow). In vehicle treated cells, we detected weak 4C signals between the bait and surrounding pre-existing and induced P300 DBS (marked red). These contacts are robustly increased upon co-stimulation. An additional six genomic viewpoints show a similar increase in interaction frequen-cies and inclusion of induced P300 binding sites in the interaction network upon ligand induction (Supplementary Fig. 8,9). To assess the interaction frequency at P300 DBS, we divided the P300 DBS that were detected in our 4C analysis (8 viewpoints) into induced and pre-existing. For each group we plotted the average of P300 ChIP-seq and 4C signal (Reads Per Kilobase per Million mapped reads (RPKM)) in control and stimulated cells. The constitutive P300 binding sites display a similar ChIP-seq and 4C signal pattern in vehicle and ligands treated cells (Fig. 3C) Importantly, induced P300 binding sites show a sig-
nificantly higher (p<0.001, t-test) 4C signal in ligand treated cells when compared to the control cells (Fig. 3D).
GR and NFκB activation enhances long-range chromatin con-
tactsThe 4C assays support the presence of long-range interaction networks 
amongst P300 DBS. Furthermore, they uncover a significant increase in contact fre-quency at induced but not at pre-existing P300 DBS (Fig. 3C-D). To further investi-gate this difference, we divided the ChIA-PET interaction sub-domains into two 
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Figure 3: GR and p65 activation dependent changes in chromatin interactions. 
(A-B) Direct comparison of chromatin contacts revealed by P300 ChIA-PET and 4C-Seq 
analyses at the ZBTB16 (A) and KLF6 loci (B). 4C-Seq bait loci are marked on each 
screenshot with a blue arrow.  Genomic regions that show a marked change in 4C sig-
nal upon TA+TNFα treatment are marked ‘red’ below the Δ4C track. (C) Direct compar-
ison of changes in average ChIP-Seq signal (left panel) and 4C signal (right panel) at all 
the constitutive P300 DBS within the ten 4C-Seq genomic view points upon TA+TNFα 
treatment. (D) Direct comparison of changes in average ChIP-Seq signal (left panel) 
and 4C signal (right panel) at all the induced P300 DBS within the ten 4C-Seq genomic 
view points upon TA+TNFα treatment. groups: sub-domains containing only pre-existing, and subdomains containing at least one induced P300 DBS. We then compared their interactome in the ChIA-PET 
profiles. However, to directly compare the two conditions, the immunoprecipita-tion-introduced bias inherent to ChIA-PET should be taken into account. The ChIP step results in a restricted representation of the interactome. A possible confound-ing factor in ChIA-PET is that chromatin regions with a higher number of binding 
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Chapter 3sites with high occupancy (RPKM) - that is higher local concentration of P300  - may 
be ChIP’ed with higher efficiency than regions with fewer binding sites and lower P300 occupancy. 
Figure 4: Ligand-induced enhancement of chromatin contacts within P300 in-
teraction sub-domains.  (A) Bar plot depicting the percentage of induced P300 peaks 
in the P300 hubs with at least five P300 peaks. (B) P300 local concentration at all P300 
interaction sub-domains that are ordered based on average P300 density (x-axis) and 
ligand-induced change in P300 concentration (y-axis). Sub-domains harboring at least 
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five P300 DBS are presented.  (C) Total number of chromatin interactions detected at 
each interaction sub-domain upon vehicle DMSO (‘blue dots’) and TA+TNFα (‘red dots’) 
treatment is presented. Sub-domains that show no more than 25% change in total 
P300 concentration (RPKM) that either harbor at least one induced P300 DBS (upper 
panel) and only constitutive P300 DBS (lower panel) are used. P-values (Mann-Whit-
ney) were generated by comparing interaction ratios (TA+TNFα/DMSO) between the 
induced and constitutive sub-domains that are within each bin (shaded area) (D) Pro-
portion of DBS to nearest first gene promoters or DBS to distal gene promoter inter-
actions identified by P300 and POLII ChIA-PET analysis. (E) Co-activation-dependent 
changes in expression of genes that are directly looped to P300 DBS. P300 DBS were 
initially ordered according to agonist induced P300 recruitment (low to high) and 
subsequently divided into 10 equal bins. The average transcriptional change of genes 
in each bin is presented. Expression of genes that are in bins harboring significantly 
repressed (grey), induced (red) and constitutive (blue) P300 DBS upon co-stimulation. 
(F) Co-activation induced changes in expression of genes that are within interaction 
sub-domains harboring either induced or only constitutive P300 DBS.In order to accurately compare the pre-existing and induced sub-domains in un-
treated and co-stimulated ChIA-PET libraries, we first estimated the local P300 con-centrations (average P300 signal) by summing up the RPKM values of P300 DBS in 
ChIA-PET interaction sub-domains harboring at least five P300 DBS with a different degree of P300 induction (Fig. 4A). With few exceptions, the co-stimulation mar-ginally affects the local concentration of P300 as compared to vehicle treated cells (less than 2 fold)  (Fig. 4B). Next, we selected subdomains that upon co-stimulation 
respond with no more than 25% change in total P300 concentration (sub-domains within the shaded area in Fig. 4B).  We computed the chromatin interaction frequen-cies (ChIA-PET interactions/sub-domain) in sub-domains that have at least one or no induced P300 DBS. In order to take into account the coverage difference of the two P300 ChIA-PET libraries we used the one-sided Mann-Whitney-Wilcoxon test. 
Interestingly, P300 hubs bearing induced P300 DBSs display a significant increase in chromatin contacts upon co-stimulation (red dots) versus vehicle treated cells (blue dots) (Fig. 4C, upper panel). Such preference is not evident in sub-domains harbor-ing only pre-existing P300 DBSs (Fig. 4C, lower panel).  Thus, preferential involvement of ligand-induced P300 DBSs in chromatin interac-
tions imply that GR and/or NFκB binding to DNA via their cognate cis-acting elements opens up the closed chromatin by recruiting chromatin-remodeling complexes. Such open chromatin regions preferentially contact other P300 DBS with a similar regu-latory factor composition and chromatin state, resulting in an interaction network 
that is synchronized upon ligand-dependent GR and/or NFκB recruitment, resulting in increased contact frequency. We preferentially detect the networks that are high-ly affected by ligand stimulation. These networks are already established prior to 
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stimulation (as detected by 4C-Seq). However, the increase of the contact frequency at induced P300 DBS upon ligand activation indicates the synchronization of such networks. We therefore consider that the (over) representation of induced interactions in our data sets may imply that a considerably larger proportion of cells in the population have the P300 protein network at these loci because the queried loci were synchro-nized by ligand treatment. 
GR and NFκB networks are enriched with their target genesFinally, we assessed the impact of agonist-induced regulatory elements and their special re-organization on transcriptional regulation using gene-body POLII 
density as a direct read-out (6). We quantified all the DBS-promoter contacts that 
were identified in both P300 and POLII interaction data sets. Importantly, 70% of 
P300 and 50% of POLII bound DBS are not contacting the nearest (first) active tran-scription start site (TSS) but a more distal TSS (Fig. 4D). Next, we computed the gene-body POLII density of genes that are connected to (induced and pre-existing) P300 DBSs. We observed a consistent positive correlation between ligand depen-
dent gene induction and P300 induction at the DBS (Fig. 4E). Genes linked to in-duced P300 DBS respond avidly to ligand induction as compared to genes that are interacting with pre-existing P300 DBS. Similarly, expression of all genes in the ago-
nist induced interaction sub-domains is significantly increased upon co-stimulation whereas genes in the constitutive sub-domains are unresponsive to agonists (Fig. 
4F). Gene ontology analysis of genes in the induced P300 hubs instigated by acti-
vation of NFκB (TNFα or co-stimulated) are enriched for GO terms associated with 
inflammatory response whereas genes linked to activated GR-induced P300 hubs are enriched for various biological processes including macromolecule metabolic 
processes. Genes connected to constitutive P300 hubs are enriched for GO terms associated with general cellular processes (Supplementary Table 3). Taken together, 
our data strongly suggests that GRE- or NFκB RE-containing latent enhancers that 
are activated upon ligand stimulation preferentially engage the GR- and NFκB target genes and subsequently modulate their expression. 
Discussion 
In this study, we have analyzed the impact of agonist-activated GR and p65 
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(NFκB) on the chromatin state and 3D organization, as well as its relation to tran-
scriptional regulation. Activated GR and p65 are mainly recruited to pre-existing regulatory elements that are pre-bound by P300, and display the epigenetic signa-ture of active enhancers prior to TF activation i.e. fall into the ‘permissive’ model cat-
egory. Our findings are in line with recent findings suggesting that signal dependent 
TFs largely access the enhancer landscape that is set up by other lineage-specific TFs 
such as PU.1, C/EBPα, AP1 (4,5,30,34). However, in ChIP-seq, we also observed de 
novo recruitment of P300 by activated GR and/or p65 to thousands of regions that subsequently acquire enhancer-like epigenetic features, in line with recent studies (5,33,34). ChIA-PET and 4C analysis indicate that these sites are involved in inter-action that would fall into the ‘instructive’ category. The chromatin signature and epigenetic changes in response to ligand activation at these induced DBSs are remi-niscent of ‘latent enhancers’ (34,47). An important question is how the agonist-induced enhancers and their target genes are spatially organized. We have compared the P300-mediated chromatin interac-
tomes before and after GR and NFκB co-activation. Using ChIA-PET against P300, we observed formation of P300-mediated long-range interactions at sub-domains bearing induced P300 DBS in response to ligand activation. With the current depth of ChIA-PET libraries, these interactions appeared to be either formed de novo (from latent enhancers) or stabilized upon ligand-induction. In 4C analysis we re-producibly detect increased interactions at induced P300 DBS; the induction in the 4C approach is however less pronounced as compared to ChIA-PET. This difference is likely due to intrinsic differences between the two assays: 4C detects long-range interactions irrespective of the presence or absence of P300 and hence is able to detect lower strength or lower frequency interactions and such that are P300 inde-pendent. In ChIA-PET, the immunoprecipitation step enriches for interactions medi-ated by P300 and does not pickup P300 independent interactions providing an all or nothing picture. Collectively and in agreement with each other, our ChIA-PET and 
4C results show that activation of GR and/or NFκB facilitates an induced interaction signal at a subset of DBSs. We interpret this increased signal as either an increase in the interaction frequency (stabilization of a network) or in the proportion of the cells that engage in such interaction (synchronization of a network). 
Recent 3C-based studies of individual loci reported on the role of GR and NFκB in long-range gene regulation (10,13,48). For example, the Lcn2 gene locus is engaged 
in multiple long-range contacts with GR DBS. In agreement with our findings, it 
60
Chapter 3
was shown that activated GR increases local chromatin interactions without dra-matic change in 3D organization. In another report exploiting the 4C approach, ac-
tivated GR was shown to bind a downstream enhancer of Tsc22d3 gene, causing a two fold increase in long-range enhancer-promoter interaction and activation of 
transcription (13). Similarly, TNFα induces chromatin interactions between distal 
NFκB bound enhancers and the promoter proximal regulatory sites of CCL2 (10). 
In contrast, a recent study based on genome wide Hi-C analysis revealed that the 
vast majority of TNFα responsive enhancers, as determined by p65 binding, show 
little change in DNA looping after TNFα treatment (16). The authors note that only 
~15% of p65 DBS display an activated enhancer signature (increase in H3K27ac sig-
nal and enhancer RNA production) upon TNFα treatment. The apparent discrepancy with our study is likely due to the differences in resolution of applied techniques. 
In agreement with Jin et al. we find that the majority of long-range interactions are pre-established and not dynamic, however, by applying ChIA-PET and high-resolu-
tion 4C we find a significant increase in long-range interactions at induced but not constitutive P300 DBS. These changes in a subset of interactions are conceivably 
difficult to pick up using a relatively low-resolution Hi-C only approach.   
One of the questions debated in the field of chromatin topology is the extent to which long-range interactions are dynamic and correlate with gene expression such as in response to extracellular stimuli or during differentiation. The ‘instructive’ model 
suggests de novo formation of long-range interactions, where lineage-specific and/or signal-induced TFs establish a new interaction landscape and affect the expres-sion of their target genes (10-14,49). Our data provides support for this model: at ligand-induced DBSs, ChIA-PET and 4C data show an increased interaction signal at 
loci that were largely closed with low or no active epigenetic marking (H3K27ac) 
but with low levels of H3K4me1, reminiscent of latent enhancers (34). Our data also provides support for the ‘permissive’ model showing that long range-interaction landscape is preformed in the absence of ligand induction. Ligand activated TFs ap-pear to join a pre-set network of enhancers and trigger transcription by lineage-spe-
cific and/or signal-induced TFs (16-18). 
Conclusions
We conclude that the ligand-activated GR and p65 induce chromatin accessi-bility, P300 recruitment, and alterations of 3D chromatin structure at a subset of 
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genomic loci. At sub-domains with induced P300 binding, activated GR and p65 fa-cilitate close spatial proximity of the induced P300 DBS with a pre-existing inter-action network and enhancement of 3D chromatin contacts. Our data suggest that ligand induction causes synchronization or stabilization of active chromatin states 
and higher order structure in a large proportion of cells to facilitate efficient regula-tion of their target genes. We speculate that this spatial clustering of regulatory ele-ments can cause an increase in the local concentration of regulatory proteins, which ultimately can enhance the transcriptional activity of associated genes. Further ex-
periments are needed to validate and expand on these findings, to elucidate the role 
of inducible TFs in long-range regulation and to firmly establish that increased phys-ical looping interaction indeed leads to increased transcription.
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Methods
Cell culture
HeLa B2 cells were maintained as described (7). Cells were cultured in Dul-
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becco’s Modified Eagle Medium (DMEM) supplemented with 10% charcoal stripped fetal calf serum (FCS) for 72-96 hours before subsequent treatment and/or har-
vesting. Cells were treated with either DMSO or 1μM of Triamcinolone acetonide (T6501, Sigma-Aldrich) for 4 hours with or without an additional treatment with 
10ng/ml Tumor necrosis factor α (T0157, Sigma-Aldrich) for the last hour. 
Chromatin immunoprecipitation and sequencing (ChIP-Seq)
ChIP was performed according to standard protocol (50) with minor modifica-
tions. Paraformaldehyde (1%) crosslinking was carried out for 10 minutes followed by the chromatin preparation as described earlier (7).  Nuclei were re-suspended in ChIP-incubation buffer at a concentration of 20x106 cells/ml and sheared (7 cycles with each cycle containing 10 sec power on and 10 sec interval) using Bioruptor(r)Plus (B01020001, Diagenode). Sonicated chromatin equivalent of 4x106 cells was incubated with relevant antibody overnight at 40C.  Antibodies against P300 (sc-585x, Santa Cruz biotechnology, Inc.), RNA-Polymerase II (MMS-126R-500, Covance, 
Inc.) H3K27ac (C15410196, Diagenode), H3K4me1 (C15410194, Diagenode) and 
H3K4me3 (C15410003, Diagenode) were used. ChIP-Seq sample preparation and sequencing was performed according to manufacturer’s instructions (Illumina) and essentially as described (6,9,51)(http://www.blueprint-epigenome.eu). 
ChIP-Seq data analysis
The image files generated by HiSeq 2000 (Illumina) were processed to extract sequence data and the 36/42 bp tags were unambiguously mapped to human ge-nome (NCBI, hg19) using the bwa aligner allowing at most one nucleotide mismatch. Reads were further directionally extended to 200bp, corresponding to the original length of the DNA fragments used for sequencing. For each base pair in the genome the number of overlapping sequence reads was determined, averaged over a 10 bp window and visualized in the University of California Santa Cruz genome browser (http://genome-euro.ucsc.edu). ChIP-Seq data sets were normalized as described (6,7) in order to eliminate the differences caused by sequencing depth/mapping ef-
ficiency.  Detection of putative P300 and RNA-POLII (POLII) binding sites was performed us-
ing MACS (version 1.4.2) (52) with the p-value <10-9.  Peaks identified by using 
each antibody in DMSO, TA, TNFα and TA+TNFα were combined in a common pool 
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Binding sites that show a significant change (median ± 2x median absolute devia-
tion; p<0.05) in signal for P300 or POLII in a treatment compared to that in vehi-
cle treated sample were regarded as dynamic binding sites. Published GR, p65 and 
POLII ChIP-Seq data that were generated in an identical experimental setup in HeLa 
B2 cells (GEO accession number GSE24518) were used in this study. 
DNase I-Seq
DNase I libraries were prepared from DMSO and TA+TNFα treated Hela B2 cells as described (http://www.uwencode.org/protocols). In brief, 5x106 nuclei 
were isolated using Buffer A (15 mM NaCl, 60 mM KCl, 1 mM EDTA, pH 8.0, 0.5 mM 
EGTA, pH 8.0, 15 mM Tris-HCl, pH 8.0, 0.5 mM Spermidine) supplemented with 0.06 
% IGEPAL CA-630 detergent. DNase I treatment (60 Units) was done for 3 minutes 
and subsequently the reaction was stopped with stop buffer (50 mM Tris-HCl, pH 8, 
100 mM NaCl, 0.10 % SDS, 100 mM EDTA, pH 8.0, 1 mM Spermidine, 0.3 mM Sper-
mine). The sample was further fractionated on 9% Sucrose gradient for 24 hours at 25000 rpm at 16 ºC. Fractions containing DNA fragments smaller than 1kb were 
purified and processed for sequencing according to the Illumina library preparation protocol. Normalized (read number equalized) DNase I data sets were used for the downstream analysis and visualization.  
ChIA-PET Library preparationChIA-PET libraries were prepared using the standard protocol (35,36). Chro-matin preparation and ChIP enrichment using P300 and POLII antibodies were 
performed as described above. Briefly, chromatin captured on magnetic beads was trimmed (blunt end), phosphorylated on 5’ ends followed by biotinylated half linker ligation. Chromatin complexes were then divided into two equal halves and two in-dependent half-linker ligation reactions were performed using half-linkers A and 
B containing specific barcodes (linker-A TAAG; linker-B ATGT). Subsequently, chro-matin complexes were eluted from the beads and two linker ligation aliquots were combined together for proximity ligation under diluted conditions. Subsequently, 
reverse cross-linked and purified circular DNA was digested using MmeI enzyme (restriction site is encoded on the linker). Next, biotinylated DNA fragments were 
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gation. Efficiency of the library preparation was evaluated by PCR and subsequent 
Gel-electrophoresis. Next, each library characterized by adaptor ligated DNA frag-
ments carrying 20bp of genomic DNA flanking the 36bp linker sequence on either 
side, were sequenced on HISeq200 (Illumina). Typical sequencing run yielding 200 million single end reads of 100bp length were generated for each library.
ChIA-PET data analysis
The first 72bp of each sequenced read carrying the complete ChIA-PET ligation product (linker plus genomic DNA) was taken for the further analysis after trim-ming the ends of each read.  Subsequently, single end sequenced reads were split 
at the linker ligation junction (linkerA/B-|-linkerA/B) and flipped to make the data compatible (similar to paired end sequencing reads) for the ChIA-PET data analysis 
pipeline (42). Average distance between binding sites (P300 and POLII) identified 
based on the ChIA-PET self-ligation PETs and the binding sites identified by ChIP-Seq were examined to ascertain the reproducibility binding sites by these methods. 
The binding sites identified by both methods were highly comparable, but a larger 
number of total binding sites were identified by ChIP-Seq due to higher sequencing depth. Therefore, we used ChIP-Seq binding sites as anchors to identify the intra- and inter-chromosomal interaction PETs. True long-range interaction signals were 
distinguished from the non-specific technical interaction noise by using the method 
described earlier (42). Briefly, interaction PETs having a PET count equal to two or 
more for P300 libraries and three or more for POLII libraries at a FDR <0.05 were 
considered as high confidence interaction clusters. We used 5 kb and 1Mb genom-
ic span as lower and upper cutoff limits respectively, to define the high confidence interaction PET data. Each interaction PET contains a pair of interacting anchors. Direct overlap (book end or 1 bp) of anchors of each cluster with that of other clus-ters was performed to identify interaction complexes or interaction sub-domains. 
Hence, the interaction clusters were further collapsed in to interaction complexes / sub-domains based on the interconnectivity of the PET clusters. 
Identification of dynamic interactions using ChIA-PET data 
setsTo minimalize the bias induced by local P300 concentration on the chromatin 
65
Glucocorticoid receptor and nuclear factor kappa-b affect 3D chromatin organizationinteractions detected by ChIA-PET, we analyzed the changes of interaction frequen-
cies per each P300 ChIA-PET defined sub-domain as follows. For each sub-domain, we counted the number of P300 peaks and calculated the P300 concentration (av-
erage ) in DMSO and TA+TNFα treated samples. All the sub-domains are ranked by 
the average P300 concentration of DMSO and TA+TNFα treatments. We discarded 
the sub-domains with less than five P300 peaks and separated sub-domains with at least one induced P300 peaks (261 sub-domains) and the ones with only constitutive P300 peaks (283 sub-domains). We plotted the number of interaction clusters iden-
tified in DMSO and TA+TNFα datasets separately, for individual sub-domains. The 
sub-domains were further filtered by the fold change of P300 concentration (>-0.3 
and <0.3) and this resulted in 131 and 206 sub-domains, respectively. Mann-Whit-ney test was adopted to investigate the agonist induced change in average chroma-tin interaction frequencies in comparable groups of subdomains that harbor only constitutive P300 DBS against those having at least one agonist induced P300 DBS. 
4C-Seq Library Preparations
4C assays were performed as described previously (46) with minor modifica-
tions. Briefly, 107 cells were cross-linked for 10 minutes with 2% paraformaldehyde, 
quenched with glycine and lysed in 50 ml lysis buffer (50mM Tris pH 7.5, 150mM 
NaCl, 5mM EDTA, 0,5% NP-40, 1% TX-100, 1X protease inhibitors) for 30 min. Nu-clei were then digested by DpnII enzyme followed by inactivation of restriction en-
zyme by incubating at 65˚ C for 20 min. The digested chromatin was subsequently 
ligated (circularized) overnight at 16˚ C with 50U T4 ligase. Ligated chromatin was 
then reverse cross-linked by incubating with proteinase K at 65˚ C and subsequent-
ly, the RNA was removed by additional incubation at 37˚ C with RNase A. The pu-
rified DNA was further digested with a second restriction enzyme of choice (BfaI, MseI or NlaIII) followed by circularization of the DNA. 4C product was subsequently 
amplified with bait-specific inverse primers (Supplementary Table 4). From each 
4C library, about 3200 or 800 ng DNA was amplified in multiple parallel PCR reac-
tions containing 200ng of DNA each, which were subsequently pooled and purified. 
Amplified bait-containing DNA fragments were ligated to NextFlex DNA barcoded 
adaptors (Bioo Scientific). Adaptor ligated DNA was purified by Agencourt AMPure 
XP purification system (Beckman Coulter), PCR amplified (8 cycles) and sequenced 
single-end on the Illumina HiSeq2000 to obtain 50bp long reads.   
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4C-Seq Data analysisTo improve the mappability of the sequence reads, we generated a reduced 
genome by extracting the sequences flanking the DpnII sites (30bp on each strand from the DpnII sites to downstream) based on build version hg19 of the human ge-nome. Then we estimated the mappability of the extracted sequences (each strand separately) and only uniquely mappable DpnII sites were considered for down-stream analysis.
All the reads from each library were parsed based on the bait-specific primer se-quence and mapped to the reduced genome using bwa (version 0.6.2) with the default parameters. The mapping data of the individual libraries are summarized (Supplementary Table 5). We initially mapped each replicate library separately and merged the replicate libraries based on their quality. 4C signal was calculated using 
a sliding window of 10Kb (±5Kb of a given DpnII site) and normalized to the total 
number uniquely mapped reads. Δ4C is the difference of 4C signal in each genomic 
bin (10kb) between the normalized DMSO and TA+TNFα data sets. 
Gene Ontology analysis
Gene ontology analysis was performed using DAVID web tool (53,54). Gene sets were analyzed for enriched gene ontology terms (biological processes) compared to human genome database as background. Fisher exact test was used to identify sig-
nificantly enriched GO terms. 
Data availability
All the ChIP-seq, ChIA-PET and 4C raw data files have been submitted to GEO 
database (GEO accession number: GSE61911). Previously published GR, p65 and 
POLII ChIP-Seq data can be accessed via GEO accession number GSE24518. 
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Supplementary text
Cross-talk between GR and NFkB leads to complex changes in 
chromatin landscapeWe (1) previously reported a staggering complexity in the cross talk between the 
GR and P65 pathways with positive and negative effects of co-stimulation with re-
spect to gene expression, DNA binding patterns of p65 and GR, and consequently for 
epigenetic makeup. An illustration of this complexity is exemplified by the TNFAIP3 locus (Supplemental Fig. 4). TNFAIP3 is a bona fide target gene of NFκB as well as GR 
that synergistic responds to co-activation by glucocorticoids and TNFα (1-3). 
To gain global insight, we co-activated GR and p65 and assessed P300 occupancy, epigenetic marking and DNaseI accessibility. Co-activation leads to de novo recruit-ment of P300 to 2884 DBS as compared to 1911 sites when adding up the induced P300 binding site obtained after single activation (2 x median absolute deviation). 
K-means clustering of these DBS identified three distinct groups. At the vast major-
ity of induced P300 sites detected following single TNFα activation (Supplemental 
Fig. 2B, C), additional activation and binding of GR did not alter the P300 occupancy 
(Supplemental Fig. 5A, I). GR appears to join a DBS that is activated by p65 in re-
sponse to TNFα treatment. Similarly, TNFα co-stimulation and binding of p65 did not notably alter the P300 inducible sites that were established upon single activa-
tion of GR (Supplemental Fig. 5A, II). At an additional ~700 DBS (Supplemental Fig. 
5A, III), co-activation of GR and p65 led to a modest synergistic increase in P300 recruitment. Taken together, we identify induced P300 DBS that are uncovered upon 
single activation of GR, P65 and their co-activation. We also analyzed changes in DNase I accessibility and epigenetic marks at all in-
duced P300 DBS (Supplemental Fig. 5B) upon co-activation of GR and P65 and compared with that of constitutive P300 DBS (Supplemental Fig. 5C). Induced P300 
DBS display a readily detectable gain in DNase I accessibility and H3K27ac upon 
co-activation of GR and P65 (Supplemental Fig. 5B, two upper panels). These loci 
are marked with H3K4me1 in un-stimulated cells, marginally gain H3K4me1 signal upon co-stimulation (Supplemental Fig. 5B, lower panel). On contrary, constitutive 
P300 DBS that are DNase I hypersensitive, marked with H3K27ac and H3K4me1 prior to ligand/s stimulation, show no further changes upon to co-stimulation (Sup-plemental Fig. 5C). Finally, P300 occupancy is also marginally reduced at a small 
subset of DBS (~400) upon co-stimulations (data not shown). 
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Supplementary figures
Figure S1: GR binds predominantly to distal binding sites. Pile-up heat map de-
picting the H3K4me1 and H3K4me3 signal around (±12 kb) all GR bound promoters 
and distal binding sites.
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Figure S2: Activated p65 induces de novo P300 depositions to latent genomic 
loci. (A) Pile-up heat map depicting the H3K4me1 and H3K4me3 signal around (±12 
kb) all p65 bound promoters and distal binding sites. (B) Pile-up heatmap depicting 
the p65 and P300 signal at all p65 bound enhancers upon vehicle, DMSO (-) and TNFα 
(+) treatment. (C) Example screenshot depicting TNFα induced P300 recruitment 
at genomic regions (red box) and recruitment of p65 at genomic loci that are pre-
marked by P300. (D) Motif occurrence at all p65 bound DBS presented as a function 
of TNFα dependent P300 recruitment (x-axis)  (top-panel); Level of shared binding of 
p65 and other TFs at all p65 bound DBS, presented as a function of TNFα dependent 
P300 recruitment (bottom-panel). (E) Level of H3K27ac, DNase I hypersensitivity and 
H3K4me1 at all p65 bound DBS (induced and constitutive P300 sites.
H3K4me3 H3K4me1
All P65 binding sites
Promoters
(1092)
DBS
(11454)
A
+-- +TNFα
P65 P300
Induced
(1001)
C
onstitutive
(10453)
B
chr17:
10 kb
P65_DMSO
P65_TNF
P300_DMSO
P300_TATNF
H3K27ac_DMSO
DNAseI_DMSO
H3K4me1_DMSO
H3K4me3_DMSO
CCL2 CCL7
150 _
1 _
150 _
1 _
150 _
1 _
150 _
1 _
150 _
1 _
50 _
1 _
75 _
1 _
75 _
1 _
32570000 32590000
C
Supplementary Fig. 2
−10000 0 10000
0
20
40
60
80
10
0
−10000 0 10000
0
5
10
15
−10000 0 10000
0
20
40
60
80
H3K27ac
H3K4me1
DNase I
Constitutive P300 DBS
Induced P300 DBS
# 
re
ad
s 
/ 4
00
 b
p
0 
10 
20 
40 
60 
80 
100 
-0.96 
-0.40 
-0.22 
-0.06 
0.08 
0.23 
0.39 
0.57 
0.78 
1.04 
1.46 
2.55 
M
ot
if 
oc
cu
rre
nc
e 
(%
) 
GR RE AP1 RE NFkB RE 
 Fold P300 induction (log   ) 2
ED
Distance from peak summit (bp)
# 
re
ad
s 
/ 4
00
 b
p
# 
re
ad
s 
/ 4
00
 b
p
74
Chapter 3
Figure S3: Large numbers of P300 bound loci are not co-occupied by GR or p65. 
(A) Average ChIP-Seq signal of GR and P300 around (±10 kb) all the P300 binding sites 
that do not show a significant GR occupancy. (B) Average ChIP-Seq signal of p65 and 
P300 around (±10 kb) all the P300 binding sites that do not show a significant p65 
occupancy.
Figure S4: Complex epigenetic changes induced by co-activated GR and p65. An 
example screenshot depicting the GR dependent (blue box), p65 dependent (red box) 
and co-stimulation dependent (black box) induced P300 DBS and constitutive DBS. 
Dynamic changes in DNase I accessibility, epigenetic modifications and RNA-POLII ac-
tivity on genes upon co-activation are noticeable characteristics of this locus.
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Figure S5: Co-activation of GR and p65 induces additional de novo P300 DBS. (A) 
Pile-up heat map depicting signal of P300, GR and p65 at three groups (p65 depen-
dent, GR dependent and co-stimulation dependent) of inducible P300 DBS that were 
identified upon co-activation of GR and p65. Motif occurrence (%) at all three clusters 
of induced P300 DBS (bar graphs). (B) H3K27ac, DNase I accessibility and H3K4me1 
signal at all induced P300 DBS upon vehicle (DMSO) and co-treatments (TA+TNFα). 
(C) H3K27ac, DNase I accessibility and H3K4me1 signal at all constitutive P300 DBS 
upon vehicle (DMSO) and co-treatments (TA+TNFα).
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Figure S6: (A) Histogram depicting the genomic proximity (localization) of P300 
binding sites identified by ChIP-Seq in relation to those identified by using ChIA-PET 
self ligation PETs. Identical comparison is performed for both DMSO and TA+TNFα 
treated data sets. (B) P300 ChIP-Seq signal at P300 binding sites commonly identi-
fied by ChIP-Seq and ChIA-PET and those binding sites that were uniquely detected 
in ChIP-Seq data set. (C) P300 ChIP-Seq signal at P300 binding sites that are either 
involved (anchor) or not involved (non-anchor) in long-range interaction as identi-
fied by ChIA-PET analysis. (D) An example screenshot depicting the P300 interaction 
subdomains, P300 ChIP-Seq binding sites in relation to topological domains as defined 
by replication timing data (www.replicationdomain.org). (E) Localization of all the 
interaction sub-domains identified by ChIA-PET analysis (P300 and POLII) in relation 
to topological domains.
ChIA-PET Vs. ChIPSeq
(P300 TA+TNFα)
Distance between peak summits
Fr
eq
ue
nc
y
−1000−500 0 500 1000
0
20
0
40
0
60
0
80
01
00
0
ChIA-PET Vs. ChIPSeq
(P300 DMSO)
Distance between peak summits
Fr
eq
ue
nc
y
−1000−500 0 500 1000
0
20
0
40
0
60
0
80
0
A B C
0
2
4
6
8
lo
g2
 R
P
K
M
Common
Unique
DMSO TA+TNFα
0
2
4
6
8
lo
g2
 R
P
K
M
Anchor
Non−anchor
DMSO TA+TNFα
chr3:
5 Mb hg19
180,000,000 185,000,000 190,000,000
Topological domains (TAD)
P300 ChIP-Seq
P300 ChIA-PET
1.36239 _
-1.36872 _
0 -
150 _
1 _
ChIA-PET interaction clusters (sub-domains)
D
E
0 20 40 60 80 100 
P300 TA+TNF  
P300 DMSO 
POLII TA+TNF  
POLII DMSO 
 ChIA-PET interaction clusters/sub-domains (%)  
across TAD  confined to TAD
Supplementary Fig. 6
77
Glucocorticoid receptor and nuclear factor kappa-b affect 3D chromatin organization
Figure S7: Reproducibility of 4C-seq biological replicates at the FKBP5 locus.
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Figure S8: Direct comparison of long-range interactions identified by P300 ChIA-
PET and 4C-Seq analyses at FKBP5, DUSP1, and BIRC3 loci.  
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Figure S9: Direct comparison of long-range interactions identified by P300 ChIA-
PET and 4C-Seq analyses at PTPN1, SULF1 and ZFHX3 loci.  
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Supplementary table
Supplementary Table 1: Overview of sequenced and mapped reads of all the 
ChIA-PET libraries.
Supplementary Table 2: List of all significant long-range interactions identified 
by P300 and POLII ChIA-PET analysis (Available online)
Supplementary Table 3: Overview of enriched Gene Ontology terms for the genes 
that are in various types of interaction subdomains.
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Supplementary	Table	1: Overview of sequenced and mapped reads of all the ChIA-PET libraries. 
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Cluster1:		Genes	in	p65	induced	P300	interaction	sub-domains	
GO	term	 P-Value	 Fisher	Exact	
response	to	wounding	 1,30E-02	 2,50E-03	
lipid	biosynthetic	process	 1,90E-02	 2,70E-03	
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TTATGTCCAC	
11	 102177
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BIRC3_enh2	 DpnII	 ACAGAATCAGT
GGGTTGATC	
ACAGAATCAGT
GGGTTGATC	
MseI	 GAGCACATAT
GGGGAAGAAA	
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DUSP1	 DpnII	 GGCATTCATTG
CCAGTGATC	
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Supplementary	Table	4:	Overview	of	restriction	enzyme	combinations	and	inverse	PCR	primer	pairs	
used	for	4C-Seq.	
Supplementary	Table	5.	Overview	of	sequenced	and	mapped	reads	of	4C-Seq	libraries	(Available	
online).	
	
Supplementary Table 4: Overview of restriction enzyme combinations and in-
verse PCR primer pairs used for 4C-Seq.
Supplementary Table 5. Overview of sequenced and mapped reads of 4C-Seq li-
braries (Available online).
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AbstractMonocyte-to-macrophage differentiation in vivo occurs in homeostasis and 
during inflammation. This differentiation is associated with changes on epigenetic 
and transcriptional levels. Here we investigate dynamics of higher-order chromatin organization during monocyte-to-macrophage differentiation and immunological 
training by Capture Hi-C. We demonstrate that despite the absence of cell division, this differentiation is associated with higher-order chromatin reorganization, in-cluding changes in A/B compartments, strengthening of TADs and their boundaries and a global gain of short-range interactions. While differentiation is associated with profound changes, immunological training does not cause spatial chromatin dynam-ics, suggesting that differentiation is the main driver of chromatin remodeling. 
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IntroductionUnder homeostatic conditions monocytes can differentiate to macrophages in vitro and in vivo (1). In steady state condition the contribution of circulating mono-
cytes to tissue macrophages is limited. However, upon inflammation, monocytes are rapidly recruited and give rise to tissue macrophages, which can effectively combat 
an infection. Upon encountering different inflammatory stimuli these macrophages 
display stimulus-specific responses, suggesting their functional plasticity(1-3). Fur-thermore, it has been recently discovered that in response to certain stimuli (e.g. Candida Albicans b-glucan) monocytes can develop an enhanced immunological response and resistance to secondary infections – a phenomenon described as “trained innate immunity” (4,5). 
Monocyte-to-macrophage differentiation and response to inflammatory stimuli are associated with extensive remodeling of the gene expression program(2,5,6). 
These changes are largely driven by combinatorial action of lineage-specific (e.g. 
PU1, EGR2) and signal-dependent transcription factors (e.g. NF-kB, IRF) that bind and activate distal regulatory elements or enhancers(7,8). Accordingly, the enhancer 
repertoire is cell-type specific, and in macrophages was shown to be shaped by the tissue microenvironment and exposure to external stimuli(3,9,10). Regulatory activity of enhancers can be exerted over large linear distances and the three-dimensional organization of chromatin controls proper communication be-tween regulatory elements. Recently, it has been demonstrated that on the Mega-base (Mb) scale chromatin is organized into two compartments: the ‘A’ compart-
ment that is generally associated with an active chromatin configuration and the ‘B’ 
compartment containing repressive chromatin(11,12). On a finer scale the A and B compartments are further partitioned into self-interacting units or topologically as-sociating domains (TADs). The majority of long-range interactions, including those between regulatory elements, occur within TADs while interactions with other TADs are relatively infrequent(13,14).
Here, we set out to characterize chromatin organization during terminal myeloid differentiation and immunological training by focusing on two closely related cell types: monocytes and macrophages. We report widespread changes in 3D chro-matin organization during monocyte-to-macrophage differentiation. With the use 
of the high-resolution capture Hi-C (CHi-C) approach(15,16), we show that mono-cyte-to-macrophage differentiation is accompanied by extensive ‘A/B’ compartment 
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Chapter 4switching, strengthening of TAD boundaries and gain of short-range interactions be-tween regulatory elements, while immunological training does not involve changes in higher-order 3D chromatin organization. 
Results
Capture Hi-C approachTo study how monocyte-to-macrophage differentiation and immunological training affect chromatin organization, human primary monocytes were isolated from healthy volunteers and differentiated into naïve macrophages by ex-vivo cul-turing for 6 days (5). Immunological training was performed by an initial exposure 
of the monocytes to β-glucan (BG) during the first 24 hours, followed by withdrawal of the stimulus and 5 days of culture (Figure 1A). We have previously demonstrated that monocyte-to-macrophage differentiation is associated with extensive epigen-etic and transcriptional remodeling, with a distinct signature associated with dif-ferent time-points during differentiation (Figure 1B) (Novakovic, et al). In order to investigate chromatin organization during differentiation and immunological train-
ing we performed CHi-C on monocytes (Day0), intermediate population (Day1/D1) and differentiated macrophages (Day6/D6), using the four basepairs (bp) cutting 
restriction enzyme DpnII. CHi-C combines genome-wide detection of chromatin interactions with target enrichment by hybridization-based capture, allowing for high-resolution detection of interactions at a selection of loci (Figure 1C). Target 
selection was based primarily on H3K27Ac dynamics during monocyte-to-macro-phage differentiation, as this mark is associated with active regulatory elements. We 
have targeted 20193 enhancers and 6826 promoters, ~40% and ~50% of which, 
respectively, were associated with a dynamic H3K27ac signal. 
All CHi-C libraries were deep-sequenced to obtain at least 250 million reads per 
library, which resulted in at least 100 million informative reads after filtering (Sup-
plementary Table1). The enrichment of the targeted regions was ~52 fold and av-
erage capturing efficiency was 56%. The uncaptured remainder of paired-end reads 
(44%) in our CHi-C samples represented conventional Hi-C reads. 
To validate the robustness of the CHi-C approach, libraries for each time-point were prepared in two biological replicates, which displayed high reproducibility (data not shown). Furthermore, global clustering of interactions revealed high similarity be-tween samples belonging to the same time-points (Figure 1D). 
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Figure 1. Three-dimensional chromatin organization profiling during mono-
cyte-to-macrophage differentiation.  (A) Schematic overview of experimental set-up 
for studying monocyte differentiation and trained immuntity. (B) PCA plots of mRNA, 
H3K27ac and H3K4me1 dynamics during monocyte-to-macrophage differentiation. 
(C) Schematic representation of CHi-C approach. (D) Global clustering of Hi-C inter-
action profiles. 
Global reorganization of 3D chromatin architecture during 
monocyte-to-macrophage differentiationTo investigate the higher-order chromatin structure globally, we analyzed our 
CHi-C data as conventional Hi-C and compared the interaction frequencies on the chromosomal level. Interestingly, in monocytes (Figure 2A, left) and Day1 cells (Fig-ure 2A, middle), we observed frequent dispersed long-range interactions, resulting in a blurred pattern on the 2D interaction matrix. In Day6 macrophages, these long-
range interactions were largely lost. The retained interactions localized to specific regions, resulting in a sparse checkerboard pattern (Figure 2A, right). To further investigate the observed contact redistribution we directly compared the differen-
tiation time-points by subtracting Hi-C interaction frequencies (Figure 2B). We ob-served a progressive increase in short-range (diagonal of the interaction matrix) and a clear decrease in long-range interactions during differentiation (Figure 2B). To quantify the observed redistribution of chromatin contacts we calculated the ra-
tio of short (<2Mb) versus long-range (>2Mb) interactions (SvL)(17). As expected, 
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Day6 macrophages displayed higher SvL (1.91 fold) than monocytes and Day1 cells (Figure 2C, yellow box). Next we were wondering whether the increase in SvL ratio 
is associated with differentiation in general or is specific for monocyte-to-macro-
phage differentiation. In order to address this question we analyzed external Hi-C 
and CHi-C datasets for several human cell types: human embryonic stem cell (hESC) 
line H1 (12), hematopoietic progenitors CD34+(15), monocytes and three subtypes 
of macrophages (M0, M1 and M2) (Javierre et al., Cell in press). Interestingly, com-
parison of these cell types (H1, CD34, Monocytes) revealed a general decrease in SvL ratio during differentiation, in contrast to an increase observed during mono-cyte-to-macrophage differentiation. Furthermore, the high SvL detected in naïve macrophages at Day6, is consistent across different macrophage subtypes (M0, M1, 
M2; data from Javierre et al., Cell in press) (Figure 2C). This indicates that a high SvL ratio, as compared to monocytes, is a general property of macrophages. 
Figure 2. Global reorganization of interaction landscape. (A) Normalized Hi-C in-
teraction maps for the q-arm of chromosome 9 in monocytes (left), Day 1 (middle), and 
Day 6 (right). The color maps for relative interaction probability are displayed on the 
same scale for each heatmap. The PC1 signal was used to define the A (orange) and B 
(blue) compartments and is displayed below each heatmap. (B) Differential heatmaps 
for the q arm of chromosome 9 in monocytes (left), Day 1 (middle), and Day 6 (right). 
The color maps are displayed on the same scale for each comparison. Red is used to 
designate enrichment in the first condition, and blue depletion. (C) The ratio of short-
range (<2 Mb) versus long-range (>2Mb) interactions (SvL) calculated for each chro-
mosome arm across the whole genome at 40kb resolution.
A/B compartment rearrangement in mature macrophagesOn a megabase (Mb) scale the genome can be partitioned into two compart-ments, A and B, which contain relatively active and inactive chromatin, respectively, 
and preferentially interact with regions belonging to the same compartment. Genes 
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the ‘B’ compartment(11). ‘A/B’ compartment organization is cell-type specific and 
~36% of the genome was shown to change compartments in at least one lineage during hESC in vitro differentiation(12). 
Figure 3. A/B compartment switching during differentiation. (A) Comparative 
PCA analysis of chromatin organization during myeloid differentiation. (B) Screenshot 
exemplifying cell-type specific A/B compartment organization. Region switching in 
H1 to CD34+ transition (yellow), monocyte-to-macrophage transition (green), CD34+ 
to monocyte transition (red) and non-dynamic (blue). (C) Heatmap of regions signifi-
cantly changing their PC1 value during monocyte-to-macrophage differentiation. “De-
crease” corresponds to regions with a decrease in PC1 in macrophages compared to 
monocytes. These regions relocate from A to B compartment or display a significant 
decrease in PC1 within the B compartment. “Increase” corresponds to regions with an 
increase in PC1 in macrophages compared to monocytes. These regions relocate from 
B to A compartment or display a significant increase in PC1 within the A compart-
ment. (D) Box plots of average expression of genes residing in regions with decreased 
(left) or increased (right) PC1 value. (E) Example screen shot of genes switching com-
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partments during monocyte-to-macrophage differentiation. ALDH3A2 gene (left) is 
belongs to B compartment in monocytes and Day1 macrophages, and relocates to A 
compartment in Day6 macrophages. ARL4A gene (right) belongs to A compartment 
in monocytes and Day1 cells and repositions to B compartment in Day6 macrophages. 
(F) PCA analysis of time-dependent changes in higher-order chromatin organization. 
SvL ratio (left) and A/B compatments (right) demonstrate that Monocytes and Day1 
macrophages are very similar, while Day6 macrophages are different.  To globally assess chromatin organization dynamics during myeloid differentiation we performed principal component analysis (PCA). As expected, hESC clustered away from CD34 and differentiated myeloid cells, indicating that differentiation is accompanied by reorganization of chromatin. Within the differentiated cells we de-
tected two distinct groups, separated on both principal components. The first group included monocytes together with Day1 cells. The second group contained fully dif-ferentiated macrophages. All macrophage subtypes displayed tight clustering, irre-spective of their subtype, indicating the similarities in their chromatin organization (Figure 3A). 
Next, we identified ‘A/B’ compartments based on the first principal component (PC1) from the PCA; positive PC1 values were assigned to the ‘A’ compartment (orange) and negative values to the ‘B’ compartment (blue) (Figure 3B). Visual in-
spection confirmed cell-type specific changes in compartment organization during myeloid differentiation. For example, we observed regions changing compartments 
early, during H1 to CD34 differentiation and remaining in the same compartment in differentiated myeloid cells (Figure 3B, yellow box), those changing compartment in monocytes and remaining in the same compartment in macrophages (Figure 3B, red box), or unchanged throughout differentiation (Figure 3B, blue box). Several studies suggest that chromatin organization is constrained during inter-phase(18,19) and mitosis is required for a region to be repositioned(20). Remark-ably, while monocyte-to-macrophage differentiation occurs without cell division(5), we observed multiple regions switching compartments (Figure 3B, green box). In 
total ~3,3% of the genome (108,9 Mb) was associated with significant changes in PC1 values during monocyte-to-macrophage differentiation, with the majority of the 
regions (~2,6%, 84,4 Mb) relocating from ‘B’ to ‘A’ or showing a strong increase in 
PC1 values within the ‘A’ compartment; and ~0,7% (24,5 Mb) relocating from ‘A’ to ‘B’ compartment or associated with decrease in PC1 value within the B compart-ment (Figure 3C). Interestingly, while monocyte-to-macrophage differentiation is associated with prominent ‘A/B’ compartment reorganization, treatment with b-glu-
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can has marginal effect (Figure 3A-C). We could identify only two regions specific for 
b-glucan treated macrophages at Day1 and none at Day6 (Supplementary Figure 1).As the ‘A/B’ compartments are suggested to be associated with relative activity state, we next analyzed the expression of genes located in changing compartments. As ex-pected, genes residing in the regions with decreasing PC1 values were associated with reduction in gene expression during differentiation (Figure 3D, left), while those associated with increased PC1 values showed gradually induced expression levels (Figure 3D, right). For example, expression of the ALDH3A2 gene is induced more than 15 fold during differentiation; accordingly, we observe this gene relocat-ing from the inactive ‘B’ compartment in monocytes to the active ‘A’ compartment in macrophages (Figure 3E, top). On the other hand, expression of the ARL4A gene de-creases 2 fold during differentiation, and the gene is relocated to the inactive B com-
partment (Figure 3E, bottom). Global gene ontology (GO) analysis of genes residing in switching compartments did, however, not reveal any enrichment in function for these genes, suggesting that multiple pathways might be affected by compartment reorganization. Lastly, we were wondering when the observed changes in higher order chroma-tin organization happen with respect to the epigenetic and transcriptional chang-
es during the differentiation process that we previously identified (Figure 1B). For this, we performed PCA analysis of SvL ratio and ‘A/B’ compartment organization for monocytes, Day1 and Day6 naïve and b-glucan trained macrophages. We observed that while transcriptional and epigenetic changes were already prominent at Day1 (Figure 1B), changes in higher-order chromatin organization were only detected at Day6 (Figure 3F), suggesting the temporal uncoupling of these events. Furthermore, 
while on the level of gene expression and H3K27ac occupancy we detected a clear difference between naïve and b-glucan exposed macrophages at Day1 (Figure 1B), we did not detect treatment-dependent changes in higher order chromatin struc-ture (Figure 3F).  
Strengthening of TAD boundaries during monocyte-to-mac-
rophage differentiationOn a Kilobase scale the ‘A/B’ compartments are further partitioned into TADs. Multiple studies suggest that TAD organization is similar between cell types and sta-ble during differentiation (13,14), while others demonstrate that TAD boundaries 
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Chapter 4can be altered (21,22). In order to investigate the TAD organization during mono-
cyte-to-macrophage differentiation we first performed TAD calling based on the 40 
Kb resolution interaction matrix. We detected ~2000 TADs in monocytes and ~3000 
TADs in macrophages. The large difference in the number of TADs that we identified in monocytes and macrophages suggests extensive remodeling of TAD boundaries. To investigate this, we assessed the boundary strength by computing and comparing the directionality index (DI) of monocytes and macrophages (13). 187 boundary re-
gions were identified as dynamic based on 4 fold change cut-off of DI. In agreement with the increased number of TADs in macrophages, all of the dynamic boundaries were stronger at Day6 (Figure 4A-B). Furthermore, increase in boundary strength was detected almost exclusively at Day6 and not at Day1, consistent with the ‘A/B’ compartment reorganization (Figure 3C). 
Figure 4. Domain-level changes in chromatin organization. (A) Heatmap displays 
directionality index (DI) values at 40 Kb resolution for the dynamic boundaries. (B) 
Normalized Hi-C interaction maps are shown for regions with dynamic TAD boundar-
ies in monocytes (top), Day 1 (middle), and Day6 macrophages (bottom). (C) Bar plot 
of CTCF binding sites distribution relative to TAD boundary. (D) Box plot of CTCF occu-
pancy ratio in Day6 macrophages over monocytes for all TAD boundaries and dynamic 
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TAD boundaries. (E) Distribution of TAD score: the ratio of intra-TAD interactions ver-
sus all cis interactions of a TAD, calculated at 40kb resolution. (F) TAD score in Day6 
macrophages (y-axis) plotted against TAD score in monocytes (x-axis). All the TADs 
were sorted by the ratio of their TAD score in monocytes and macrophages and binned 
into 10 groups. (G) Heatmaps showing the enrichment of several chromatin features 
(epigenetic modifications, accessibility, CTCF binding, A/B switching) in the TADs in 
each of the 10 bins. As TAD boundaries are frequently associated with insulator protein CTCF (13) and CTCF is required for their maintenance (23), we hypothesized that strengthening of the TAD boundaries during monocyte-to-macrophage differentiation is associat-
ed with differential CTCF binding. Motif analysis of TAD boundaries confirmed the frequent association of the CTCF motif with TAD boundaries in monocytes and mac-rophages (data not shown). Thus, we performed CTCF ChIP-seq in monocytes and 
macrophages and compared the binding profiles. As expected, CTCF binding was 
enriched at TAD boundaries (Figure 4C), however, no significant difference in CTCF 
occupancy was found at macrophage-specific boundaries (Figure 4D). Hence, the increase in boundary strength in macrophages is not caused by increased CTCF oc-cupancy in macrophages. Motif enrichment analysis at dynamic boundaries did not reveal any additional motif besides CTCF, associated with these boundaries. 
Terminal myeloid differentiation alters intra-TAD chroma-
tin organizationThe higher number of called TADs in macrophages might also suggest changes in chromatin organization within the TADs. In order to investigate this, we comput-ed the TAD score – a ratio of intra-TAD interactions to inter-TAD interactions on the same chromosome (12,24). For most of the TADs we observed a gradual increase in TAD score during monocyte-to-macrophage differentiation (Figure 4E-F), sug-gesting that domains become more compartmentalized in macrophages. Next, we wanted to assess how the increase in TAD score relates to changes in the epigenetic and transcriptional landscape. For this, we have sorted the TADs based on the fold change of their score in macrophages compared to monocytes and divided them in ten bins. Bin one contained the least and bin ten the most changing TADs. These dy-namic TADs were not enriched for differentially expressed genes (data not shown), suggesting that increased compartmentalization of these TADs is not directly asso-ciated with transcriptional changes of genes within them. We reasoned that while we could not detect a distinct gene expression pattern as-
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epigenetic changes. For each bin we calculated the enrichment of activating (H3K-
27Ac, H3K4me1, H3K4me3) and repressive (H3K27me3, H3K9me3) histone marks, 
accessible chromatin and insulator protein CTCF (Figure 4G). Interestingly, the least changing TADs appeared to be associated with activating marks, open chromatin and switching from active to inactive compartment. The most changing TADs on the 
other hand, were found to be enriched for the repressive histone mark H3K27me3 
and switching from inactive to active compartment (Figure 4G). One possible sce-nario is that upon relocation from inactive to active compartment, these TADs are 
restricted to prevent the spread of H3K27me3 or long-range repression of regulato-ry elements in neighboring TADs. 
DiscussionIn this study we analyzed changes in chromatin organization during termi-nal myeloid differentiation and induction of trained immunity. Notably, mono-cyte-to-macrophage differentiation occurs in the absence of cell division (5), allow-ing us to uncouple differentiation-induced changes in chromatin organization from changes associated with cell division.  During differentiation changes in gene expression are accompanied by reorganiza-tion of chromatin (12,25). As these changes often coincide, it is not clear whether changes in gene expression and nuclear repositioning are causally related. Some lo-
cus-specific studies suggested that changes in gene expression and epigenetic make-
up are sufficient to induce repositioning of the locus (26,27), while others suggest that changes in gene expression do not lead to repositioning (28). During mono-cyte-to-macrophage differentiation extensive epigenetic and transcriptional chang-es can already be observed at Day1 (Figure 1B). Remarkably, no changes in high-er-order chromatin organization could be detected at this time-point (Figure 3F). This temporal uncoupling of chromatin reorganization and transcriptional/epigen-etic changes might suggest their independence and lack of a direct causal relation, 
although further experimental validation is required to confirm this observation.Changes in ‘A/B’ compartments during differentiation have been recently reported for hESC and several derived lineages (12). The extent of the observed changes var-
ied dependent on the assayed lineage, from ~3,8% in mesendoderm to 25% in mes-enchymal stem cells (MSC)(12). In monocyte-to-macrophage differentiation, despite 
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of the close relation between the two assayed cell types, ~3,3% of the genome was associated with compartment changes, comparable with the extent of changes be-tween hESC and mesendoderm. Interestingly, during hESC differentiation the major-ity of the detected compartment changes were associated with an ‘A’ to ‘B’ transition and expansion of the inactive ‘B’ compartment(12), while in monocyte-to-macro-phage differentiation the majority of the switching regions relocated from the ‘B’ to 
the ‘A’ compartment. Recent reports suggest that stimulus-specific responses during macrophage activation are associated with distinct transcription factor networks, which are signal-dependent and operate in a permissive chromatin environment (2,27,29). Thus, the general increase in PC1 values and switching to the ‘A’ compart-ment can be associated with the establishment of an open, permissive transcrip-tional environment in macrophages, which might attribute to their functional plas-ticity (3). In line with this, our analysis revealed that macrophage subtypes, while different on transcriptional, epigenetic and functional levels (2,29), share a similar chromatin organization (Figure 3A).Coinciding with a global gain of short-range interactions and switching to the ‘A’ compartment, we observed that topological domains in macrophages adopt a more pronounced organization (Figure 4A-B,E-F). This reorganization is accompanied by strengthening of TAD boundaries, which appears to be CTCF-independent (Fig-
ure 4A-D). However, other insulator proteins might be responsible for increase in boundary strength. For instance, a component of the cohesin complex, SMC1A, is 
strongly up-regulated (~3 fold) during monocyte-to-macrophage differentiation (data not shown). The cohesin complex is required for insulator activity of CTCF(30) and its depletion leads to reduction of intra-TAD interactions(31), in agreement with pattern observed in monocytes, where SMC1A is lowly expressed. Alternatively, boundary strength might be affected by combinatorial action of insulator proteins (32), similar to boundary remodeling in response to temperature stress in Drosoph-ila (21). 
Functionally, the most changing TADs display strong enrichment of the H3K27me3 
chromatin mark (Figure 4G). We speculate that stronger insulation of these TADs might be required to prevent the spreading of repressive chromatin or, alternatively, to prevent an aberrant activation of inactive genes within the domain, as has been recently reported for the HOX locus (23). Future genome editing experiments of dy-
namic TAD boundaries are required to address their functional significance in mac-rophage biology.
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Chapter 4In summary, we show that monocyte-to-macrophage differentiation is accompanied by extensive changes in three-dimensional chromatin organization, including a glob-al increase in short-range interactions in macrophages, changes in ‘A/B’ compart-ments and reorganization of TADs. Treatment with b-glucan, on the other hand, does not alter higher-order chromatin organization, suggesting that differentiation, rath-
er than treatment-specific activation is the main driver of changes in the three-di-mensional chromatin structure of macrophages.
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Materials and methods
Monocytes isolation from healthy donorsAll primary cells were isolated from healthy volunteers who gave written informed consent (Sanquin Blood bank, Nijmegen, the Netherlands). Peripheral blood mono-
nuclear cells were isolated by centrifugation in Ficoll-Paque (GE Healthcare), fol-lowed by removal of T cells using an additional Percoll gradient. Monocytes were 
purified from PBMCs using negative selection in an LD column magnet separator, 
with beads for CD3+ (T cells), CD19+ (B cells) and CD56+ (NK cells) positive cells 
(Miltenyi biotech), yielding >95% pure monocytes. Successful isolation of mono-
cytes was confirmed with FACS, as previously described (5).
In vitro Monocyte to macrophage differentiation and induc-
tion of trained innate imunityMonocytes were differentiated into resting macrophages by ex vivo culture in 
RPMI 1640 medium (Sigma Aldrich) with 10% Human Serum. Trained innate immu-
nity was induced by treatment with 5 μg/mL BG for 24 hours, followed by washout and 5 days in culture. Establishment of tolerance or training in the resulting mac-
97
Higher-order chromatin reorganization during monocyte-to-macrophage differentiationrophages at day 6 was determined by TNF and IL6 release at 24 hours following LPS stimulation using ELISA. For ChIP-seq, 10x106 monocytes were seeded in 10cm 
dishes, for CHi-C at least 50x106 monocytes were seeded in 14cm dishes.
Chromatin immunoprecipitation and sequencing (ChIP-seq)
ChIP was performed according to standard protocol (33) with minor modifica-
tions. Paraformaldehyde (1%) crosslinking was carried out for 10 minutes followed by the chromatin preparation as described earlier (34).  Nuclei were re-suspend-ed in ChIP-incubation buffer at a concentration of 20x106 cells/ml and sheared (5 cycles with each cycle containing 10 sec power on and 10 sec interval) using Bio-ruptorPico (B01060001, Diagenode). Sonicated chromatin equivalent of 4x106 cells was incubated with 15 ml CTCF antibody (ab70303, Abcam) overnight at 40C. ChIP-Seq sample preparation and sequencing was performed according to manufactur-er’s instructions (Illumina). 
Capture Hi-C (CHi-C)
The Capture Hi-C experiment was divided into two parts, in-nucleus Hi-C and 
ss-DNA probe capture enrichment. In-nucleus Hi-C was carried out as described in Nagano et al., 2015. DpnII was used as the restriction enzyme. On beads DNA am-
plification PCR was carried out with 7-9 cycles to generate around 1μg of Hi-C li-brary DNA. ssDNA probe capture step was carried out using the protocol provided 
by Roche NimbleGen Inc. (http://sequencing.roche.com/products/nimblegen-seq-cap-target-enrichment/seqcap-ez-system/seqcap-ez-developer.html) optimized for the probe capture library. Libraries were
indexed using NEXTflex adapters (Bioo-Scientific Corporation, Austin, TX, USA) and 75bp or 43bp paired-end sequencing was performed on Illumina instruments us-ing TruSeq reagents (Illumina, San Diego, CA, USA), according to manufacturer’s in-structions.
ChIP-Seq data analysisTags were mapped to the reference human genome hg19 using the Bur-rows-Wheeler Alignment Tool2 (BWA). Before down stream use, duplicates reads 
and reads with a MAPQ<15 were discarded. For visualization the number of overlap-ping sequence reads was determined per base pair, averaged over a 10 bp window 
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Chapter 4and visualized in the UCSC genome browser (http://genome.ucsc.edu). For com-
parison bam files were normalized to the same number of reads. Peakcalling was performed with MACS2((35)) software and peaks for monocytes and macrophages were merged. RPKM was calculated for merged peaks.  
Capture Hi-C data analysis
MappingThe two ends of paired-end reads were mapped to the reference human ge-
nome (hg19) separately, using BWA MEM with default parameters. Reads were fil-
tered based on mapping quality score (both ends MAPQ≥10) and PCR duplicates were removed. Reads were also removed if the two ends are from the same DpnII fragment. 
Normalization 
First, all the reads were treated as from conventional Hi-C library. Raw contact matrices were generated for individual libraries and merged libraries from the same 
condition at fixed locus sizes of varying resolution including 20kb, 40kb, 100kb, 200kb. For each matrix, the contacts on the diagonal bins were considered informa-tive and removed. Normalization of the matrices were then performed with iterative 
correction (36) in Bioconductor R package “HiTC” with default settings. After nor-
malization, the rows of the contact matrix approached a constant. Differential Hi-C 
interaction maps were calculated by subtracting the second condition from the first one using the normalized contact matrices of 200kb resolution. 
SvL ratio calculationThe short-range versus long-range, or SVL ratio, was calculated as described previously(17). In this calculation, we considered only intra-chromosomal interac-tions within a single chromosome using the normalized contact matrices of 40kb resolution. 
A/B compartment identificationA/B compartment calling was performed at 40kb resolution as previously de-
scribed (12). Briefly, the normalized 40kb contact matrices were used to calculate 
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Higher-order chromatin reorganization during monocyte-to-macrophage differentiationthe expected contact frequency between two 40-kb bins given the distance separat-ing them in the genome. A sliding 200kb window was then used with a step size of 40kb to generate an observed/expected matrix. This matrix was then used to cal-culate the Pearson correlation matrix and subsequently used for principal compo-
nent analysis. Genomic regions were identified displaying significant changes in A/B 
compartment, if these regions show statistically significant variability in PC1 values across all conditions using ANOVA and at least 40 difference in the PC1 values in any two conditions. 
TAD calling
Topological domains were systemically identified based on the directionality 
index (DI) score using a Hidden Markov Model (HMM) previously described (13)
at 40kb resolution. The final coordinates of topological domains were manually in-spected and calibrated according to all the domains obtained above. The intra-do-main contact score (TAD score) was calculated as described previously (25). 
Capture Hi-C
CHiCAGO CHi-C analysis package (http://regulatorygenomicsgroup.org/chica-
go) was used to call significant contacts. To improve quality, the whole genome was windowed into 3 DpnII site tiles. Virtual baits were created using the 3 DpnII site 
tiles that contain at least one targeted DpnII fragment. Interactions were filtered 
based on interaction score and number of reads (score≥5 and at least 2 reads). 
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Supplementary Figures
Figure S1: An example screenshot of two loci (MYC and KCNA10) displaying ‘A/B’ 
compartment switching in Day1 BG but Day1 RPMI samples.
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Supplementary Tables
Table S1: Mapping statistics for CHi-C samples
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Supplementary	tables	
Sample	 Total	Reads	 Both	ends	
mappable	
(excluding	self-
ligation)	
%	 Without	
duplicates	
%	 At	least	one	
end	on	
target	
%	
BG_D1_9275	 293	000	000	 177	549	943	 60,60	 143	983	910	 81,09	 76	924	458	 53,43	
BG_D1_9277	 380	000	000	 205	017	442	 53,95	 165	024	135	 80,49	 89	346	643	 54,14	
BG_D6_9362	 230	000	000	 155	336	842	 67,54	 138	209	895	 88,97	 85	847	334	 62,11	
BG_D6_9364	 500	000	000	 296	808	352	 59,36	 99	046	526	 33,37	 63	266	147	 63,88	
Mono_9166	 310	000	000	 160	112	769	 51,65	 118	689	480	 74,13	 63	676	617	 53,65	
Mono_9791	 330	000	000	 188	563	474	 57,14	 127	844	646	 67,80	 61	530	622	 48,13	
RPMI_D1_9276	 295	000	000	 171	829	878	 58,25	 143	714	146	 83,64	 77	338	820	 53,81	
RPMI_D1_9278	 331	000	000	 176	812	116	 53,42	 144	404	836	 81,67	 81	821	872	 56,66	
RPMI_D6_9363	 275	000	000	 183	272	628	 66,64	 170	697	135	 93,14	 95	713	847	 56,07	
RPMI_D6_9499	 275	000	000	 146	605	390	 53,31	 114	382	476	 78,02	 69	262	680	 60,55	
Supplementary	Table	1:	Mapping	statistics	for	CHi-C	samples	
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AbstractIn 11q23 leukemias the N terminal part of the MLL gene is fused to over 60 
different partner genes. In order to define a core set of MLLr targets, we investigated the genome wide binding of the MLL-AF9 and MLL-AF4 fusion proteins and associ-
ated epigenetic signatures in AML. We uncovered both common as well as specific 
MLL-AF9 and MLL-AF4 target genes, which were all marked by H3K79me2, H3K-
27ac, and H3K4me3. Apart from promoter binding, we also identified MLL-AF9 and 
MLL-AF4 binding at specific subsets of non-overlapping active distal regulatory ele-ments. Despite this differential enhancer binding, MLL-AF9 and MLL-AF4 still direct a common gene program, which represents part of the RUNX1 gene program and 
constitutes of CD34+ and monocyte specific genes. Comparing these datasets iden-
tified several zinc finger transcription factors as potential MLL-AF9 co-regulators. 
Together, these results suggest that MLL-fusions collaborate with specific subsets of TFs to deregulate the RUNX1 gene program in 11q23 AMLs. 
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Introduction
Mixed Lineage Leukemia (MLL), encoded by the Lysine (K)-specific Methyl Transferase 2A (KMT2A) gene at 11q23, is a H3K4me3 depositing protein active during early development. MLL rearranged (MLLr) leukemias are responsible for 
about 10% of all Acute Lymphoblastic and Myeloid Leukemias (ALL/AML)(1). The N-terminal CXXC-domain containing DNA binding part of the MLL gene can by ge-nomic translocation be fused to over 60 different fusion partners(2). The two most common fusion partners, AF9 (MLLT3) and AF4 (AFF1), are found in 30% of MLLr 
AML and 66% of MLLr ALL cases respectively(3).The most prevalent fusion partners (including AF9 and AF4) are present in the Su-per Elongation Complex (SEC), therefore leading to a general MLLr mechanism of action despite being composed of different proteins(4,5). The SEC normally binds to RNA polymerase II and facilitates transcriptional elongation. In MLLr leukemias, the SEC is tethered to the DNA binding domain of MLL via the fusion partner, lead-ing to aberrant transcription of MLL target genes. Next to that, AF9 as well as other fusion partners such as ENL, AF10, and AF17 are present in the DOT1L complex 
(DOTCOM). This deposits H3K79me2 on actively transcribed genes, leading to ab-
errant H3K79me2 deposition in these subsets of MLLr induced leukemias(6-8). As such, a promising avenue for treatment of MLLr induced leukemia is inhibition of DOT1L(9,10). Furthermore, AMLs in general and MLLr leukemia in particular have been shown to be sensitive to inhibition of BET family proteins such as BRD4 which regulate transcription elongation via P-TEFb at promoters and enhancers(11-14). MLL fusion proteins have also been shown to interfere with RUNX1(15-17), and modulate PU.1 via its distal regulatory elements(18). Moreover, MLLr and other AMLs are sensitive to inhibition of mediator kinases(19), linking modulation of distal regulatory ele-ments to execution of the MLLr leukemic program. Thus far, genome-wide maps of MLL binding are only available in mouse models of AML(7), human ALL(20-22), and of MLL-AF6 in the human AML cell line ML-2(23). No reports to date have described genome-wide MLL-AF9 and -AF4 binding in hu-man AML.
Here, we set out to investigate the molecular mechanisms and targets of MLLr in-duced AML. For this, we characterized the genome wide binding, epigenetic signa-ture and gene expression program of wildtype (wt) MLL, MLL-AF9 and MLL-AF4 in 
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Chapter 5human AML cells. We show that MLL-fusion proteins bind in a ‘broad’ mode elongat-ing over the gene body as well as in a ‘sharp’ mode stalled on the TSS, in addition to non-genic elements, such as distal enhancers. We show that MLL-AF9 and MLL-AF4 share only a subset of target genes, yet show enrichment for the same pathways in 
both the shared as well as the MLL-AF9 and MLL-AF4 specific gene sets. These target 
genes are marked by H3K79me2, H3K4me3, and H3K27ac enrichment as well as by 
RUNX1 occupancy and constitute a mixture of CD34+ and monocyte expressed gene sets. Together these results suggest that in MLLr AML the RUNX1 mediated progen-itor to monocyte differentiation program is deregulated. 
Results
MLL-fusions and wild type MLL show a broad and sharp bind-
ing mode
To investigate the binding sites of MLL-AF9 we used THP-1 cells that express both wt MLL as well as MLL-AF9, but not wt AF9 (Figure 1A-B, S1A). Using antibod-ies against the N-terminus of MLL-1 (ab1542/ab1547) and the C-terminus of AF9 (ab1327/ab1474) (Figure 1A) in ChIP-qPCR showed enrichment for the canonical 
HOXA MLL-fusion target region in THP-1 cells (Figure 1C), while HOXA7 and MEIS1 were, in contrast to expectations(24-26) not enriched. Subsequently, we performed 
ChIP-seq experiments using MLL and AF9 antibodies in THP-1 MLLr cells which con-
firmed enrichment on the HOXA locus for both antibodies (Figure 1D, top). Inter-estingly, we observed that both MLL and AF9 show not only ‘broad mode’ enriched regions elongating over gene bodies (Figure 1D, middle), but also ‘sharp mode’ en-riched regions on target promoters and enhancers (Figure 1D, bottom).
Using MACS2 for defining sharp peaks and HOMER for defining broad regions (see 
materials and methods), we identified 16,099 unfiltered MLL occupied regions in 
THP-1 cells (Table S1). Of these, 8217 were ‘broad mode’ (mean length ~12kb) and 
7882 ‘sharp mode’ (mean length ~4.6kb) (Figure 1E, left). Analysis of the genomic distribution revealed that the ‘broad mode’ peaks cover more TSS regions (Figure 1E, right), while the ‘sharp mode’ peaks seem to occur in intergenic regions more often. 
Since AF9 was not expressed from its endogenous locus in THP-1 cells (Figure 1B, 
S1A), we defined MLL-AF9 binding peaks as those MLL binding sites which show a high AF9 signal, and MLL-wt binding events those that show a low AF9 signal (Fig-
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ure 1F). This distilled our list of MLL occupied regions down to 1,613 high confi-dence MLL-AF9 fusion binding sites, including known AML and MLLr targets such as HOXA9, CDK6, MYB, MYC, JMJD1C, FOXP2, FLI1, RUNX1, PBX3, BCL2, and BRD4, as 
well as 439 high confidence MLL-wt binding sites (Table S1). 84% of these MLL-AF9 
binding sites are ‘broad mode’, versus 58% of wild type MLL binding sites (Figure 
1G, left), and they occupy more TSS regions as compared to wild type MLL (Figure 
1G, right).As MEIS1 occupancy and expression is near universal for all MLL fusion induced AML and ALL(27,28), we investigated the MEIS1 locus in THP-1 cells using our ge-
nome-wide data (Figure S1B). This corroborated our ChIP-qPCR finding that MEIS1 
is not bound by MLL-AF9 and not expressed in THP-1 cells, as it is marked only by 
H3K4me3 at its promoter, but not by MLL, AF9, H3K27ac, or H3K79me2. MEIS1 ex-pression in MLL fusion induced AML has been shown to be especially important for the initial transformation of the leukemic cells in mouse models(29-32). It is there-
fore conceivable that at some point since the original establishment of the THP-1 cell line in 1980(33), the locus was silenced and its role in leukemic maintenance taken over by another TALE class protein such as e.g. PBX3, which is expressed and bound 
by MLL-AF9 in THP-1 cells.
In order to further validate our findings, we performed additional ChIP-seq exper-iments against MLL (ab1542) and AF9 (ab1474) in one MLL-AF9 positive AML pa-
tient and repeated the MLL ChIP-seq in THP-1 cells with an antibody targeting a different epitope (ab1547). ChIP-seq signal intensity at our designated MLL-AF9 binding regions shows a good enrichment in all three cases (Figure S1C). This indi-cates our selected MLL-AF9 targets are not only bound by the fusion protein in the cell-line system, but also in more plastic primary cells.As MLL-AF9 induced AML has previously been studied in various mouse models, 
e.g. Bernt 2011, Zuber 2011, and Guenther 2008(7,34,35), we set out to compare 
our MLL-AF9 target genes with target genes identified in mice. We found a rela-
tively minor overlap of 12-23% between our set and the various mouse sets (Table S2), which was about the same range of overlap found between the different mouse studies. This indicates that while a core set of targets is present in both human and mouse models, mouse models do not fully recapitulate the situation in human leu-kemogenesis. 
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Epigenetic signature of MLL-AF9 target genesAs MLLr leukemias have been suggested to alter the epigenetic signature of affected cells, we compared the epigenetic state of the MLL-fusion with wt MLL tar-
get genes focusing on H3K4me3, H3K79me2 and H3K27ac. For this we took the set 
of high confidence MLL-AF9 and MLL-wt binding events overlapping with RefSeq hg19 genes, identifying 962 MLL-AF9 and 76 MLL-wt target genes, corresponding 
to 11% and 1% of all expressed genes (RPKM>0.5, cut off based on RPKM distribu-tion) respectively (Figure 2A). Promoters of MLL-AF9 target genes were marked by 
H3K4me3 and H3K27ac, while a H3K79me2 signal on gene bodies decreasing in 
Figure 1: Genome wide binding patterns of MLL and AF9 in THP-1 cells. (A) Sche-
matic representation of MLL, AF9 and MLL-AF9. Antibody binding locations are indi-
cated with dotted lines, primer regions used in (B) with a filled line. (B) rt-qPCR exper-
iments (n=5) in THP-1 cells with primers against the C and N termini of MLL and AF9 
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normalized to GAPDH. The N-terminus of AF9 is not expressed, indicating that there is 
no wild type expression of AF9 in this cell line. ***p<0.001 (Welch’s t-test). (C) ChIP-qP-
CR experiments using two anti-MLL-1 and two anti-AF9 antibodies in THP-1 cells and 
primers for HOXA7 -9, -10 and MEIS1. (D) ChIP-seq overview of MLL and AF9 binding 
at the HOXA, ZEB2, and CDKN2C loci in THP-1 cells. (E) Classification of MLL and AF9 
binding events in ‘broad’ and ‘sharp’ modes. Left: boxplot showing dispersion of peak 
lengths. Right: barplot showing genomic distributions. (F) Classification of MLL-AF9 
and MLL wild type binding events. Average profiles showing ChIP-seq signal intensities 
for MLL-AF9 and MLL-wt binding events in THP-1 cells. (G) Left: Distribution of MLL-
AF9 and MLL wild type binding events in ‘broad’ and ‘sharp’ mode. Right: Genomic dis-
tribution of MLL-AF9 and MLL wild type binding events in ‘broad’ and ‘sharp’ modes.the 5’ to 3’ direction was observed (Figures 2B, C top), indicating that these genes are actively transcribed. A similar pattern was seen on wild type MLL target genes, and a random pool of expressed genes, albeit with a mildly reduced signal strength 
for H3K79me2 (p=3.79e-10 and p<2.2e-16, respectively) (Figure 2C, middle, bot-
tom). The lower occupancy of H3K79me2 was also reflected by a lower level of gene expression of wild type MLL targets as opposed to MLL-AF9 target genes, as de-termined by RNA-seq (Figure 2D). This suggests fusion target genes are higher ex-pressed, in concordance with the paradigm that MLLr activates MLL target genes by aberrant elongation.
Pathway enrichment analysis of MLL-AF9 target genes revealed a significant (Benja-
mini-Hochberg adjusted p-value < 1e-6) enrichment of immune system, hemostasis, and adaptive immune system pathways (Figure S1D, top). MLL-wt target genes, in 
contrast, only revealed enrichment for the PDGFRB pathway (Figure S1D, bottom), often involved in translocation events leading to myeloproliferative disorder(36). Motif analysis(37) of MLL-AF9 targets revealed enrichment of the ETS, AP2 and 
C2H2-Zf family, while the POU family was depleted over background (Figure 2E, top 
left). Wt MLL target genes were enriched for motifs recognized by C2H2-Zf and ETS families, while the NR family was depleted over background (Figure 2E, top right). Direct comparison of MLL-AF9 and MLL-wt targets revealed both gene sets as sim-ilar in terms of motif enrichment, except for the NR and AP-2 motif families, which were enriched in the MLL-AF9 target gene set (Figure 2E, bottom). This suggests MLL-AF9 mediated deregulation of NR and AP-2 signaling might be involved in ab-errant hematopoietic and immunological processes.
Similarities of MLL-AF9 and MLL-AF4 binding patternsTo identify common MLL-fusion targets we expanded our analysis by including an MLL-AF4 expressing AML. As both MLL-AF9 and MLL-AF4 are thought to bind to 
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Figure 2: Epigenetic signature of MLL target genes. (A) Distribution of expressed 
genes (RPKM>0.5), silent genes, MLL-AF9, and MLL wt target genes. (B) Overview of 
AF9, MLL, H3K79me2, H3K27ac and H3K4me3 binding, and transcriptional activity at 
the ZEB2 locus in THP-1 cells. (C) Average signal of H3K27ac, H3K4me3 and H3K79me2 
at MLL-AF9 (top), and MLL wild type (middle) target genes, as compared to a random 
set of expressed genes (bottom) (D) Expression levels of MLL-AF9 and MLL wild type 
target genes ***p<0.001 (Welch’s t-test). (E) Motif families enriched over background 
in MLL-AF9 target gene promoters (top left), MLL wild type target gene promoters 
(top right), and motif families in MLL-AF9 target gene promoters enriched over MLL 
wild type target gene promoters (bottom).targets via the SEC, we set out to assess the subset of MLL target genes commonly 
bound by the fusion proteins. First, we created genome-wide binding profiles for 
MLL, AF4, H3K4me3, H3K79me2, and H3K27ac, as well as an RNA-seq expression 
profile in MV4-11 AML cells expressing the MLL-AF4 fusion protein (Figures 3A, 
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S2A-B). As before, we divided the unfiltered MLL targets (28656) in ‘broad mode’ 
(18782) and ‘sharp mode’ (9874), and by rate of AF4 occupancy filtered them down to fusion (2560) and wild type (828) binding events (Figures 3B, S2C-D, Table S3), 
showing a similar distribution as in THP-1 cells (Figure S2E). Expression of MLL-
AF4 target genes (1722, identified by overlapping the high confidence fusion binding 
events with RefSeq hg19 genes) was significantly higher than MLL-wt genes (308) (Figure 3C). Epigenetic signatures and pathway enrichments were also comparable 
to MLL-AF9 AMLs (Figure S2F-H), suggesting both MLL-AF9 and MLL-AF4 use simi-lar molecular mechanisms to induce leukemia. 
Figure 3: Comparison of MLL-AF4 and MLL-AF9 target genes. (A) Overview of AF4, 
MLL, H3K79me2, H3K27ac and H3K4me3 binding, and transcriptional activity at the 
ZEB2 locus in MV4-11 cells. (B) Genomic distribution of MLL-AF4 and MLL wild type 
binding events in ‘broad’ and ‘sharp’ modes. (C) Expression levels of MLL-AF4 and MLL 
wild type target genes. ***p<0.001 (Welch’s t-test) (D) Distribution of MLL-AF9 specific 
and MLL-AF9 and MLL-AF4 common target genes (top). Distribution of MLL wild type 
target genes in THP-1 and MV4-11 (bottom). (E) Average signal of H3K4me3, H3K27ac 
and H3K79me2 on MLL-AF4 and MLL-AF9 common and specific target genes. (F) Ex-
pression level of MLL-AF9 target genes shared (+) or not shared (-) by MLL-AF4 in THP-
1 and MV4-11 cells (left). Expression level of MLL-AF4 target genes shared (+) or not 
shared (-) by MLL-AF9 in THP-1 and MV4-11 cells (right). ***p<0.001 (Welch’s t-test)Comparing the MLL-AF9 and MLL-AF4 target gene sets (Table S4) revealed that a 
significant (p=1.98e-11) 29% (277) of MLL-AF9 target genes are also targeted by MLL-AF4 (Figure 3D, top), including known MLLr targets such as BCL2, HOXA9, MYB and BRD4. In contrast, only 3% of wild type MLL target genes found in THP-1 were targeted by wild type MLL in MV4-11 (Figure 3D, bottom). Next, we analyzed the activity of these common MLL-fusion and MLL wild type target genes versus MLL-
AF9 and -AF4 specific target genes. Common MLL-AF9 and MLL-AF4 target genes, 
Figure 3
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as well as those specific for MLL-AF9 and -AF4 show a comparable level of H3K27ac 
and H3K4me3 (Figure 3E), while H3K79me2 is slightly lower in MLL-AF9 AMLs. The 
presence of H3K79me2 signal on MLL-AF4 target genes confirms the deposition of this histone tail mark also on MLL-AF4 targets in AML(22,38).The gene expression levels as determined by RNA-seq are comparable for shared fu-
sion targets in THP-1 and MV4-11, while the MLL-AF9 and -AF4 specific target genes 
are lower expressed in MV4-11 and THP-1 respectively, with median RPKM values 
of 23 and 17 for the MLL-AF9 specific target genes and 25 and 18 for the MLL-AF4 
specific target genes respectively (Figure 3F). Together, this indicates that the set of shared MLL-fusion target genes might represent a ‘core’ set of targets important for driving the leukemic potential of both MLL-AF9 and -AF4.
Interplay of MLLr target genes with RUNX1 and CTCFAs RUNX1 is a known factor in several types of translocated AML and ALL(39-42) and has been suggested to be involved in MLLr leukemias(15,16,43), we in-vestigated RUNX1 DNA-binding in MLL-fusion induced AML. Next to that, it was recently shown that MLL translocated leukemias are affected by mediator kinase in-hibition(19). The mediator complex(44) is associated with regulation of RNA-poly-merase II at promoters and distal regulatory elements. Cohesin, important for the establishment of promoter-enhancer interactions, co-localizes with CTCF(45) and mediator(46). Cohesin mutations are prevalent in non-translocated AMLs(47) and CTCF is implicated in T-ALL(48). Therefore, we investigated CTCF binding at MLL-fu-
sion targets, as a proxy for mediator/cohesin binding. CTCF(49) (GSM1335528) and RUNX1 show enrichment on MLL-AF9 target genes, while the signal on wild type MLL genes is slightly lower for RUNX1 and almost absent for CTCF (Figure 4A, S3A). 
22% (215) of MLL-AF9 target gene promoters are occupied by CTCF, versus 11% 
for MLL-wt target genes. For RUNX1 this overlap is 80% (767) and 61% (46), re-spectively (Figure 4B, left). Moreover, RUNX1 co-occupied MLL-AF9 target genes are higher expressed than MLL-AF9 target genes without RUNX1 co-occupancy (Figure 4B, right). As RUNX1 binding to MLL-AF4 target genes in MV4-11 cells follows a 
similar pattern as discussed for MLL-AF9 in THP-1 cells (Figure S3B), together these results suggest that targeting the RUNX1 gene program is a common feature of MLLr AMLs.
 
115
MLL fusions target RUNX1 program in AML
Figure 4: Characterization of MLL-AF9 bound distal regulatory elements. (A) Av-
erage signal of RUNX1 and CTCF on MLL-AF9 and MLL wild type target genes. (B) Rate 
of co-occupancy of MLL-AF9 and MLL wild type target genes by RUNX1 and CTCF (left). 
Expression level of MLL-AF9 target genes grouped by RUNX1 co-occupancy. ***p<0.001 
(Welch’s t-test) (right) (C) Average signal on MLL-AF9 (left) and MLL wild type (right) 
bound enhancers for H3K4me3 and H3K27ac (top), MLL and AF9 (middle), and 
RUNX1, CTCF and H3K79me2 (bottom). (D) Genomic distribution of MLL-AF9 and MLL 
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wild type enhancers (top left). Co-occupancy of MLL-AF9 and MLL wild type bound 
enhancers by CTCF, H3K79me2 and RUNX1 (top right). Expression levels of MLL-AF9 
and MLL wild type intergenic enhancers (bottom left). Expression level of MLL-AF9 
bound enhancers grouped by H3K79me2 co-occupancy. *p<0.05 (Welch’s t-test) (E) 
Motif family enrichment for MLL-AF9 bound enhancers. (F) Overview of HOXA locus in 
THP-1 cells showing alignment of AF9, MLL, H3K79me2, H3K4me3, H3K27ac, RUNX1 
and RNA expression signal with the HOXA TAD boundary (grey box). (G) Pathway en-
richments of active genes nearest to an MLL-AF9 bound enhancer within the same 
TAD. (H) Long range interactions from the BCL2 and PHLPP1 promoters as measured 
by 4C in THP-1 cells (black bars, q<0.01) aligned with MLL, AF9 and H3K27ac ChIP-
seq patterns on MLL-AF9 bound enhancers (gray boxes). Arrows highlight examples of 
interactions of the baited promoters with MLL-AF9 bound enhancers.
MLL-fusion binding at distal regulatory regionsMLLr leukemias have largely been described to function via aberrant elonga-
tion of MLL target genes. However, as we noticed a significant portion (~25%) of 
MLL-AF9 and MLL-wt peaks occurring in distal regions (Figure 1G, right), we next set out to characterize these putative MLL bound enhancers. Overlapping distal 
MLL peaks with H3K27ac peaks yielded 342 MLL-AF9 bound and 75 MLL-wt bound 
active enhancers with high H3K27ac and low H3K4me3 signal (Figure 4C, top and middle, Table S5). Interestingly, while RUNX1 was detected on both MLL-AF9 and 
MLL-wt enhancer peaks, CTCF and H3K79me2 signals were specific for MLL-AF9 bound enhancers (Figure 4C bottom, S4A). As MLL-AF9 and MLL-wt enhancers occupy both intergenic as well as intronic re-gions (Figure 4D, top left) we further characterized only the set of MLL-bound in-tergenic enhancers to prevent mixing gene body and intronic enhancer chromatin 
signatures. A higher percentage of MLL-AF9 bound enhancers (39%) than MLL-wt 
bound enhancers (12%) was marked by H3K79me2 (Figure 4D, top right). This might 
reflect aberrant deposition of the histone mark by DOT1L tethered to the MLL-AF9 fusion protein. RUNX1 differences were less striking, while a CTCF peak is present 
in 50% of all MLL-AF9 bound intergenic regions, versus 11% for MLL-wt, pointing towards increased interaction with mediator for the MLL-fusion bound enhancers. 
Next to that, MLL-AF9 bound intergenic enhancer regions showed a significantly higher expression of enhancer RNA than MLL-wt bound regions (Figure 4D, bottom 
left), with MLL-AF9 bound intergenic regions co-occupied by H3K79me2 showing 
an even higher expression (Figure 4D, bottom right). Taken together, these findings indicate that MLL-AF9 bound enhancer regions are epigenetically more activated 
than their wild type counterparts, and might show aberrant H3K79me2 deposition and expression due to the binding of the MLL-fusion protein.
117
MLL fusions target RUNX1 program in AML
Next, we wondered how distal binding sites identified in MV4-11 cells for the MLL-AF4 fusion would compare to the MLL-AF9 bound enhancers, as a difference in distal regulatory elements could potentially explain the difference in gene expression we 
found between the MLL-AF9 and MLL-AF4 specific target genes (Figure 3F). MLL-
AF4 active distal binding regions were similarly grouped based on H3K27ac (al-
though average H3K27ac signal was lower as compared to MLL-AF9 distal regions), MLL and AF4 signal (Figure S4B, Table S5). Unlike the MLL-fusion target genes, there 
was virtually no overlap (2%) between MLL-AF9 and MLL-AF4 enhancers, indicat-ing that the core set of common target genes might be regulated by a variable set of regulatory regions in the different MLL-fusions. Interestingly, we observed the same 
decrease in co-occupancy of H3K79me2 on MLL-AF4 versus MLL-wt intergenic en-hancers, while RUNX1 co-occupancy was slightly higher in the wild type set, and no 
significant difference in enhancer RNA expression between MLL-AF4 and wild type MLL intergenic enhancers was observed (Figure S4C). This could indicate that as the epigenetic landscape of MLL-AF9 and MLL-AF4 bound active enhancers is similar 
except for a lower H3K27ac signal, transcriptional activity of these elements might be restricted to MLL-AF9 based leukemia, potentially either as a result of differences 
in complex presence (DOTCOM vs. SEC) or H3K27ac occupancy.Next, we set out to determine the genes these enhancers are potentially interacting with. The majority of MLL- fusion bound enhancer regions are located between 5 
and 500 kb from the nearest TSS (Figure S4D-E). However, as the TSS closest to an 
enhancer is not necessarily the one it acts upon, we refined our list of closest genes by comparison with topologically associating domain (TAD) data and by including 
active genes only. For this, we combined the CTCF binding data in THP-1 with TADs 
in human monocytes as determined by HiC (T.K., S.W. and H.S., in preparation) to get an approximate distribution of TADs. Subsequently, we linked the MLL-AF9 bound 
enhancers to the closest active (H3K27ac marked) gene within the same TAD, result-ing in 247 genes putatively regulated by MLL-AF9 bound enhancers, including BCL2, 
PHLPP1, RUNX1 and SPI1 (Table S6). We confirmed that our THP-1 TAD list includes the boundary at the 5’ of the HOXA cluster, as described in THP-1 cells(49) (Figure 4F) and performed further validation using 4C-seq experiments on the promoters of 
BCL2 and PHLPP1, both MLL-AF9 target genes identified in this study, as bait. This 
allowed to confirm interactions formed by these promoters with MLL-AF9 bound 
active enhancers (Figure 4H). 
Interestingly, of the 247 genes regulated by MLL-AF9 occupied enhancers, 25% (61) 
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are MLL-AF9 promoter/gene body occupied genes, which is significantly (p<0.0001) 
more than in a random selection of genes. Next to that, GSEA pathway analysis of this 
set of 247 genes revealed a strong enrichment for cancer (q<1e-5), CMYB (q<1e-5), 
acute myeloid leukemia (q<1e-4), and immune system (q<1e-4) pathways (Figure 
4G) providing a strong indication that these genes and their putative enhancers are indeed implicated in MLL-AF9 mediated leukemogenesis and/or maintenance. 
Expression of MLL-AF9 targets in primary cellsFinally, we compared gene expression of MLL-fusion cell lines and primary 
AML blasts to CD34+ hematopoietic progenitor cells and primary human monocytes 
(Table S7). We established that patient blasts cluster separately from CD34+ cells and monocytes (Figure 5A), Next, we focused on the subset of MLL-fusion target genes and investigated their spread by principle component analysis (PCA) (Fig-ure 5B, Table S9). We found that primary MLL-fusion samples and cell lines differ 
from monocytes by one principle component (PC1), and from CD34+ cells by an-
other (PC2), which is confirmed by functional analysis of PC1 associated pathways (Figure 5C, top left) and analysis of the average RPKM of genes in PC1 in the vari-ous cell types, which revealed a higher spread of expression levels for this subset in monocytes (Figure 5C, bottom left). Analogous functional analysis of PC2 revealed 
enrichment for pathways more associated with dividing (CD34+) progenitor cells 
(Figure 5C, top right) and an average CD34+ RPKM with a higher spread (Figure 5C, bottom right). Together, this suggests that AML associated MLL-fusions impose a block during monocyte differentiation.To identify the TFs that cooperate with MLL-fusion in driving leukemogenesis, we investigated whether the expression of 878 TFs associated with the MLL-fusion 
enriched motif families (Figures 2E,4E, S2H, S4F) is different between MLL-fusion 
positive cells, CD34+ cells and monocytes. We identified 146 TFs differentially ex-pressed in one or more cell types (Figure 5D, green dots, Table S9). Subsequently, 
we filtered these TFs based on an RPKM cut-off of 5 in at least one sample, similar-ity of the MLL-AF9 samples, and a deviation from the mean in the same direction in at least 2 samples, and clustered the remaining 74 TFs on expression pattern in 
monocytes, CD34+ cells, and MLL-AF9 and MLL-AF4 expressing cells, revealing 6 TF clusters (Figure 5E), each of which is differentially expressed in MLL-AF9 cells as compared to normal cell types or MLL-AF4 expressing cells and potentially 
119
MLL fusions target RUNX1 program in AML
Figure  5: Gene expression levels of MLL-AF9 patient blasts as compared to CD34+ 
cells, monocytes, and AML blasts. (A) Distance based clustering on the expression of 
all hg19 refSeq genes. (B) PCA analysis on the expression of MLL-AF9 target genes. (C) 
Pathway enrichments for MLL-AF9 target genes in PC1 (top left) and PC2 (top right). 
Expression levels of MLL-AF9 target genes in PC1 (bottom left) and PC2 (bottom right). 
(D) Distribution of differentially expressed AP2, C2H2-Zf, ETS, NR, POU, and T-box TFs. 
Green dots: Benjamini-Hochberg adjusted p-value < 0.01 and fold change > 4; Orange 
dots: Benjamini-Hochberg adjusted p-value < 0.05; Red dots: fold change > 1. (E) Eu-
clidean distance clustering of 74 TFs expressed significantly different in MLL-AF9 cells 
versus monocytes, CD34+, and MLL-AF4 cells. (F-G) Mean RPKM of MLL-AF9 AML high 
(F) and low (G) expressed TFs in CD34+ cells (n=3), THP-1 (n=2), MV4-11 (n=1), Mono-
cytes (n=3), MLL-AF9 blasts (n=5), AML-ETO blasts (CGA, n=7), CBFß-MYH11 blasts 
(CGA, n=11), MLLr blasts (CGA, n=11), PML-RAR blasts (CGA, n=16), and other AMLs 
(CGA, n=134).
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involved in co-regulating MLL-AF9 binding sites. To confirm this specificity, we com-pared the clustering results to expression in other types of AML (Ley et al.(50)). 
This identified 3 factors, ZNF521, ZNF433 and ZNF532 for which expression (Figure 5F) was increased in MLL-AF9 positive cells only, suggesting these collaborate with MLL-AF9 in deregulating gene expression and driving leukemogenesis, and several 
tumor suppressing factors, such as ETV3, NR4A1, and EGR2 whose expression (Fig-
ure 5G) is down regulated in MLLr as well as all other types of AML included in the 
analysis. Deregulation of e.g. ZNF521, NR4A1, and EGR2 has indeed previously been implicated in AML(51-53).
In summary, these results show that MLL-fusion target genes identified in this study 
can be divided in a group behaving more like CD34+ cells and a group behaving more like monocytes. Similarly, expression of TF family members whose motifs were enriched under MLL-AF9 and -AF4 target genes and enhancers can also be classi-
fied as CD34+ like, monocyte like, or MLLr specific. Disturbance of the normal gene expression patterns of both direct MLLr targets and co-regulating TFs potentially produces the leukemogenic phenotype witnessed in MLL translocated AML.
DiscussionIn this study, we investigated the genome wide binding and epigenetic signa-ture of MLL-AF9, MLL-AF4, and wild type MLL in AML derived cell lines carrying the 
respective MLL-fusions. Enrichment of H3K79me2, H3K27ac, and RUNX1 signal was 
high on both MLL-AF9 and MLL-AF4 target genes. Enrichment of H3K79me2 con-
firms that deposition of this histone modification on aberrantly activated MLL-fusion target genes is also a feature of MLL-AF4 induced AML, as was shown for MLL-AF4 
in murine and human ALL models(22,38). Deposition of H3K79me2 is possibly de-regulated in all MLLr acute leukemias involving a component of the SEC, via indirect 
association of the SEC with DOT1L via AF9 or ENL(54,55). However, as H3K79me2 is enriched on all activated genes in general, and not just on aberrantly activated 
MLL-fusion targets, inhibiting DOT1L function to non-specifically stop H3K79me2 deposition(9,56) may introduce deleterious off-target effects.
Enrichment of H3K27ac on aberrantly activated MLLr target gene promoters -and BRD4 being an MLLr target- corroborates the facilitating role of bromodomain pro-teins in transcription of MLLr targets(57), as evident from AML susceptibility to BET inhibition(58). This suggests a positive feedback loop where transcription of MLLr 
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MLL fusions target RUNX1 program in AMLtargets is facilitated by BRD4, and BDRD4 is transcribed because it is an MLLr target.
The large overlap between MLLr and RUNX1 binding sites and the identification of RUNX1 as an MLLr target gene suggests that MLLr AML deregulates a (subset of) the RUNX1 program, important for hematopoietic development(59). This is reminiscent 
of the way the CBFß-MYH11 oncofusion modulates expression of RUNX1 targets(39) and AML1-ETO can increase expression of a subset of RUNX1 targets(60,61). To-gether with aberrant expression of genes such as MYC in most AML subtypes(62,63) this hints at the existence of a core set of genes, including a subset of the RUNX1 program, that is important for leukemic transformation and maintenance in  trans-location induced AML.In addition to MLL-fusion binding to promoter regions as expected by the consensus of MLLr acting through aberrant activation of MLL target genes, we determined a 
significant number of MLL-fusion binding sites at active distal regulatory elements 
enriched for H3K27ac, H3K79me2, and RUNX1, and in close proximity to genes en-riched for pathways related to leukemia. In light of this, it seems likely that MLLr does not only act directly on their target genes but can also modulate expression of target genes via distal regulatory elements. The MLL-AF4 and MLL-AF9 bound en-hancers showed almost no overlap, indicating that each MLLr subtype has a distinct enhancer repertoire. This is in line with several studies linking differences in ac-quired and innate resistance to BET inhibition in various AML cell lines and different clones to a dynamic or variable enhancer landscape(12,64). Moreover, MLL-AF9 bound enhancers are enriched for CTCF binding, which is in line with MLLr AML cells being responsive to treatment with mediator kinase in-hibitors(19). This suggests an active role for MLL-AF9 in modulating the chromatin conformation to facilitate target gene expression via interference with the interplay between CTCF, RAD21 (cohesin), and the mediator complex(65,66).We extracted an extended set of core MLLr target genes including known targets such as MYC, RUNX1, BCL2, and CDK6, which can potentially be used to develop new 
strategies for combating MLLr leukemias, for instance by fine-tuning the targeting of existing potential treatments such as inhibition of DOT1L(7,9,56), BLC2i(67) or BET(11) to MLL-fusion target genes only. Next to that, the uncovered sets of MLL-
AF9 and MLL-AF4 specific target genes such as ZNF521 and CDKN2A respectively, 
indicate that each specific fusion partner also has its own unique binding signature, which may potentially be exploited against MLLr blasts with resistance against a more general treatment such as BET inhibition(57).
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Chapter 5Lastly, we show that gene expression of MLL-AF9 target genes can be divided in 
CD34+ like and monocyte like groups, thereby keeping the MLL-AF9 positive leuke-
mic cells in a state between CD34+ progenitor cells and fully differentiated mono-cytes. Likewise, TFs from families with motifs enriched under MLL-fusion targets 
can be divided in CD34+ like, monocyte like, and MLLr specific groups, uncovering TFs like ZNF521 and ZNF433 that are indirectly involved in expression or selection of MLLr target genes, and tumor suppressing TFs like ETV3 and NR4A1 that are down regulated in MLLr leukemias. Interestingly, ZNF521 is also an MLL-AF9 target, suggesting a feed-forward loop of ZNF521 and the MLL-AF9 leukemic program.
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Materials and Methods
Cell culture
THP-1(33) and MV4-11(68) cells were routinely cultured in RPMI 1640 sup-
plemented with 10% FCS and 1% pen/strep at 37 °C in a humidified incubator with 
5% CO2. Mycoplasm status was determined every 6 months.
Patient SamplesBone marrow samples from MLL-AF9 positive AML patients were collected at 
diagnosis. The study was conducted in accordance with the Declaration of Helsinki and institutional guidelines and regulations (CMO 2013/064). Patient data are sum-marized in Table 1.
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Table 1: Patient data
Patient ID  Sex Age Blast (%)AML_MLLAF9_1 M 25 96AML_MLLAF9_2 M 1 45AML_MLLAF9_3 F 45 45AML_MLLAF9_4.1 F 27 62AML_MLLAF9_4.2 F 27 62AML_MLLAF9_5 F 40 95
ChIP and ChIP-SeqChromatin from cell lines was harvested as described(69). ChIPs were per-
formed using antibodies against MLL-1, AF9, AF4, RUNX1, H3K4me3, H3K27ac, and 
H3K79me2 and analyzed by quantitative PCR or sequencing. Relative occupancy was calculated as fold over background, for which the promoter of the Myoglobin gene was used.
RT-qPCR and RNA-seq
Total RNA was extracted with TRIzol (Invitrogen) or RNAsol (GenDepot), treat-ed with DNAse on column (Qiagen) and analyzed by reverse transcriptase quantita-
tive PCR or strand specific sequencing. 
Illumina high-throughput sequencingChIP-seq and RNA-seq libraries were prepared according to manufactur-
er’s instructions. All data can be downloaded from the Gene Expression Omnibus 
GSE79899, GSM1631708, GSM1704846, and GSM1704847, or through the Blue-print DCC (http://dcc.blueprint-epigenome.eu/#/home).
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Supplementary information
Extended Experimental Procedures
Chromatin immunoprecipitation (ChIP)
Cells were crosslinked with 1% formaldehyde for 20 min at room temperature, 
quenched with 0.125 M glycine and washed with three buffers: (i) PBS, (ii) 0.25% 
Triton X 100, 10 mM EDTA, 0.5 mM EGTA, 20 mM HEPES pH 7.6 and (iii) 0.15 M NaCl, 
10mM EDTA, 0.5 mM EGTA, 20mM HEPES pH 7.6. Cells were then suspended in ChIP 
incubation buffer (0.15% SDS, 1% Triton X 100, 150 mM NaCl, 10 mM EDTA, 0.5 mM 
EGTA, 20mM HEPES pH 7.6) and sonicated using a Bioruptor sonicator (Diagenode) for 20 min at high power, 30 s ON, 30 s OFF. Sonicated chromatin was centrifuged 
at maximum speed for 10 min and then incubated overnight at 4°C in incubation 
buffer supplemented with 0.1% BSA with protein A Dynabeads (Thermo Fisher Sci-
entific) and 2 µg of antibody. Beads were washed sequentially with four different 
wash buffers at 4˚C: two times with a solution of 0.1% SDS, 0.1% DOC, 1% Triton, 
150 mM NaCl, TEE (10mM Tris pH 8, 0.1mM EDTA and 0.5mM EGTA), one time with a similar buffer but now with 500 mM NaCl, one time with a solution of 0.25 M LiCl, 
0.5% DOC, 0.5% NP-40, TEE and two times with TEE. Precipitated chromatin was 
eluted from the beads with 400 μl of elution buffer (1% SDS, 0.1 M NaHCO3) at room 
temperature for 20 min. Protein-DNA crosslinks were reversed at 65°C for 4 h in the presence of 200 mM NaCl, after which DNA was isolated by Qiagen column. Anti-bodies and primers for qPCR can be found below. For qPCR, relative occupancy was calculated as fold over background, for which the promoter of the Myoglobin gene was used.
rt-qPCRcDNA was synthesized using iScript (BioRad) and enrichment was calculated as fold 
over the 1st exon of GAPDH.
Strand-specific RNA-seqTotal RNA was extracted by TRIzol (Invitrogen), subjected to on-column DNase 
treatment (Qiagen) and the concentration was measured with a Qubit fluorometer (Invitrogen). 250 ng of total RNA was used with the Ribo-Zero rRNA Removal Kit (Illumina) to remove ribosomal RNAs according to manufacturer instructions. 16 
µl of purified RNA was fragmented by addition of 4 µl 5x fragmentation buffer (200 
mMTris acetate pH 8.2, 500 mM potassium acetate and 150 mM magnesium acetate) 
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and incubated at 94°C for exactly 90 s. After ethanol precipitation, fragmented RNA 
was mixed with 5 μg random hexamers, followed by incubation at 70 °C for 10 min 
and chilling on ice. We synthesized first-strand cDNA with this RNA primer mix by 
adding 4 μl 5× first-strand buffer, 2 μl 100 mM DTT, 1 μl 10 mM dNTPs, 132 ng of ac-
tinomycin D, 200 U SuperScript III, followed by 2 h incubation at 48 °C. First strand 
cDNA was purified by Qiagen mini elute column to remove dNTPs and eluted in 34 μl 
elution buffer. Second-strand cDNA was synthesized by adding 91.8 μl, 5 μg random 
hexamers, 4 μl of 5× first-strand buffer, 2 μl of 100 mM DTT, 4 μl of 10 mM dNTPs 
with dTTP replaced by dUTP, 30 μl of 5× second-strand buffer, 40 U of Escherichia 
coli DNA polymerase, 10 U of E. coli DNA ligase and 2 U of E. coli RNase H, and incu-
bated at 16 °C for 2 h followed by incubation with 10 U T4 polymerase at 16 °C for 
10 min. Double stranded cDNA was purified by Qiagen mini elute column and used 
for library preparation as described in the KAPA Hyper Prep protocol. We incubated 
1 U USER (NEB) with adaptor-ligated cDNA at 37 °C for 15 min followed by 5 min at 
95 °C before PCR to ensure strand specificity.Illumina high-throughput sequencingChIP-seq libraries were prepared from precipitated DNA of 5 million cells (5-8 pooled biological replicas) for MLL, AF9, AF4, and RUNX1, or from 1 million cells for 
the histone tail modifications. End repair was performed using Klenow and T4 PNK. A 3’ protruding A base was generated using Taq polymerase and adaptors were li-
gated. The DNA was loaded on E-gel and fragments corresponding to ~300 bp (ChIP 
fragment + adaptors) were excised. The DNA was isolated, amplified by PCR and 
used for cluster generation and sequencing on the Genome Analyzer (Illumina) or 
HiSeq 2000 (Illumina). For RNA-seq 250 ng of RNA was used for ribosomal RNA 
depletion with RiboZero (Illumina) and subsequent strand specific library prepara-tion. The 42-50 bp tags were mapped to the reference human genome hg19 using 
the Burrows-Wheeler Alignment Tool (BWA) for ChIP-seq or TopHat2 (Bowtie2) for RNA-seq. For each base pair in the genome, the number of overlapping sequence reads was determined, averaged over a 10 bp window and visualized in the UCSC genome browser (http://genome.ucsc.edu).
4C-Seq
4C assays were performed as described previously(1) with minor modifications. 
Briefly, 107 cells were cross-linked for 10 minutes with 2% paraformaldehyde, 
quenched with glycine and lysed in 50 ml lysis buffer (50mM Tris pH 7.5, 150mM 
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NaCl, 5mM EDTA, 0,5% NP-40, 1% TX-100, 1X protease inhibitors) for 30 min. Nuclei were then digested by DpnII enzyme followed by inactivation of restriction enzyme 
by incubating at 65˚ C for 20 min. The digested chromatin was subsequently ligated 
(circularized) overnight at 16˚ C with 50U T4 ligase. Ligated chromatin was then 
reverse cross-linked by incubating with proteinase K at 65˚ C and subsequently, the 
RNA was removed by additional incubation at 37˚ C with RNase A. The purified DNA was further digested with MseI as a second restriction enzyme, followed by circu-
larization of the DNA. 4C product was subsequently amplified with bait-specific in-verse primers (see Primers – 4C-seq). From each 4C library, about 3200 ng DNA was 
amplified in multiple parallel PCR reactions containing 200ng of DNA each, which 
were subsequently pooled and purified. Amplified bait-containing DNA fragments 
were ligated to NextFlex DNA barcoded adaptors (Bioo Scientific). Adaptor ligated 
DNA was purified by Agencourt AMPure XP purification system (Beckman Coulter), 
PCR amplified (8 cycles) and sequenced paired-end on the Illumina NextSeq 500 to obtain 50bp long reads. 
Bioinformatic analyses
AlignmentTags were mapped to the reference human genome hg19 using the Burrows-Wheel-
er Alignment Tool(2) (BWA) for ChIP-seq or TopHat2(3) (Bowtie2(4)) for RNA-seq 
samples. SamTools(5) was used for creation and manipulation of BAM files for each 
experiment. Before down stream use, duplicates reads and reads with a MAPQ<15 
were discarded for ChIP-seq samples. For RNA-seq, only reads with MAPQ<15 were discarded. For ChIP-seq visualization, the number of overlapping sequence reads was determined per base pair, averaged over a 10 bp window and visualized in the 
UCSC genome browser (http://genome.ucsc.edu). For strand specific RNA-seq vi-sualization, separate tracks were created for both strands, which were displayed in 
pairs using UCSC trackHubs.
Peak callingPeak calling software MACS2(6) was used to detect ‘sharp’ mode binding sites of 
MLL and all binding sites of H3K4me3, H3K27ac, RUNX1, and CTCF with a q-value 
cut off of 1e-6 or 1e-9.  For ‘broad’ mode MLL binding sites and all H3K79me2 bind-
ing sites, HOMER2 findPeaks software(7) was used with the following settings: -fdr 1e-6 -size 5000 -minDist 10000. 
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MLL binding site classification
MLL binding sites from MACS2 and HOMER2 were merged with bedTools(8), and split again in ‘sharp’ and ‘broad’ mode peak lists using a length cut-off of 7500bp, or split into ‘fusion’ and ‘wild type’ binding sites by means of fusion partner sig-nal strength. For this, AF9 (or AF4) tags within MLL binding regions were counted and adjusted to represent the number of tags within a 1 kb region. Subsequently the percentage of these tags as a measure of the total number of sequenced tags of the sample was calculated. Finally, the AF9 (or AF4) normalized tag counts per MLL binding site obtained in this way were binned, and the MLL binding sites containing 
the upper quartile of AF9 (or AF4) normalized tag counts were identified as MLL-fu-sion binding sites, while the MLL binding sites containing the lower quartile of AF9 
(or AF4) normalized tag counts were identified as MLL wild type binding sites. Over-
laps between gene sets were tested for significance using a hypergeometric test with 23503 refseq hg19 genes as total universe.
Tag countingTags within a given region were counted and adjusted to represent the number of tags within a 1 kb region. Subsequently the percentage of these tags as a measure of the total number of sequenced tags of the sample was calculated and displayed 
as heat maps with the Fluff package(9) or as average profiles with ngs.plot soft-ware(10).
Peak distribution analysis
To determine genomic locations of binding sites, corresponding peak files were ana-lyzed using a script that annotates binding sites according to all RefSeq hg19 genes. With this script every binding site is annotated either as promoter (2000 bp window around the Transcription Start Site), exon, intron or intergenic (everything else). 
MLL binding sites were identified as gene targets or distal binding sites based on 
this classification. Distal MLL binding sites were further characterized as active en-
hancers based on intersection with H3K27ac peaks using BED tools.
Motif analysis
Peaks were culled to 300 bp, and used with Gimme Motifs(11) software to deter-mine underlying known motifs. Motifs were subsequently grouped into motif fam-ilies and their relative occurrence as opposed to either motifs called from genomic annotation and length matched random regions or a second set of called peaks (e.g. 
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Pathway Enrichment analysis
Specific sets of binding regions / genes were analyzed for molecular pathways en-
richments using the Gene Set Enrichment Analyses (GSEA)(12,13) web tool with the ‘canonical pathways’ (CP) collection.
Expression analysis
Normalized (RPKM) values for all refSeq hg19 genes were calculated using HOMER2 analyzeRepeats software. Various subsets of these RPKM tables (e.g. only MLL-fu-sion bound genes) as well as the set of Ley et al. AML patients blast RPKMs(14) were loaded into an R 3.2.3 environment(15) for visualization as box and bar plots. 
Raw tag count tables were also generated using HOMER2 analyzeRepeats and load-ed into R for distance and Pearson correlation clustering and PCA analyses using the DESeq2 package(16). After PCA analysis, the top contributing genes per prin-cipal component (PC) were extracted by converting the rotation values per PC into 
z-scores and filtering out only those genes with sigma > 1.5.
4C-seq analysis
A reduced genome was generated by extracting the sequences flanking DpnII sites (30bp on each strand from the DpnII sites to downstream) based on build version hg19 of the human genome. Only uniquely mapped DpnII sites were considered for downstream analysis.
Reads from each library were parsed based on the bait-specific primer sequence and mapped to the reduced genome using bwa (version 0.6.2) with the default parame-
ters. 4C signal was calculated using a sliding window of 10Kb (±5Kb of a given DpnII site) and normalized to the total number uniquely mapped reads. Interactions were called using the r3Cseq R package(17) using an aggregate window of 2 kb and an FDR q-value cut-off of 0.05.
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Antibodies
PrimersChIP-qPCR
cDNA
4C-Seq
	 134	
Reads	from	each	library	were	parsed	based	on	the	bait-specific	primer	sequence	
and	mapped	to	 the	reduced	genome	using	bwa	(version	0.6.2)	with	 the	default	
parameters.	4C	signal	was	calculated	using	a	sliding	window	of	10Kb	(±5Kb	of	a	
given	DpnII	 site)	 and	 normalized	 to	 the	 total	 number	 uniquely	mapped	 reads.	
Interactions	 were	 called	 using	 the	 r3Cseq	 R	 package(17)	 using	 an	 aggregate	
window	of	2	kb	and	an	FDR	q-value	cut-off	of	0.05.	
	
Antibodies	
Anti-	 Epitope	 Cat.	No.	 Manufacturer	
MLL-1	 QGQESDSSETSVRGP-C	 AT71-Ab1542	 Diagenode	
MLL-1	 PIFDNFRPPPLTPED-C	 AT73-Ab1547	 Diagenode	
AF9	 SSASSPLHHEPPPPL	L-C	 AT22-Ab1327	 Diagenode	
AF9	 FTPSQTRQQGP	RSI	-C	 AT23-Ab1474	 Diagenode	
AF4	 -	 Ab31812	 Abcam	
H3K4me3	 -	 pAb003-050	 Diagenode	
H3K27ac	 -	 pAb-174-050	 Diagenode	
H3K79me2	 -	 Ab3594	 Abcam	
RUNX1	 -	 Ab23980	 Abcam	
	
Primers	
ChIP-qPCR	
Target	 Region	 Forward	 Reverse	
HOXA7	 Promoter	 AGCTGGGAGACGTTGACTTT	 GACAGGCCGGACTTAGACTC	
HOXA9	 Promoter	 GGGAGACGGGAGAGTACAGA	 GCTCTACGATGGGGTTTGTT	
HOXA10	 Promoter	 ACCGCAGGATGAAACTGAAG	 TTCCCCCAGAAAACAACAAA	
MEIS1	 Promoter	 CGGGTTCTAGCATTCTGGTC	 TCTCCCTCTTTGCAAGTGCT	
MB	 Promoter	 GGATTGAGTCTGCCCAGG	 GATGGAAGGGCAGAGGTG	
cDNA	
Name	 Target	Region	 Forward	 Reverse	
MLL-
N1	
KMT2A	
N-terminus	
TCAGCTGCAGGGAAGAAAGG	 CTATAAACCGCCGAGGGGTC	
MLL-
N2	
KMT2A	
N-terminus	
TGTGAGAATCTTTCAGATGAGATGT	 CTTTTTCAAGGGCCAGTCGC	
MLL-C	
KMT2A	
C-terminus	
CCACAGAGTGTGGGAGGAAC	 AGAGGAACTGGATGCCAAGC	
AF9-N	
MLLT3	
N-terminus	
TGGCTAGCTCGTGTGCCGTG	 CCGGACCGCGTACGAACACC	
AF9-C	
MLLT3	
C-terminus	
GCAGCCGAAGTCGCAGAGTTA	 AGGGTGGTGGAGGTTCGTGATGT	
GAPDH	 1st	exon	 GCCTCAAGATCATCAGCAATGC	 TGGTCATGAGTCCTTCCACGA	
	 134	
Reads	from	each	library	were	parsed	based	on	the	bait-specific	primer	sequence	
and	mapped	to	 the	reduced	genome	using	bwa	(version	0.6.2)	with	 the	default	
parameters.	4C	signal	was	calculated	using	a	sliding	window	of	10Kb	(±5Kb	of	a	
given	DpnII	 site)	 and	 normalized	 to	 the	 total	 number	 uniquely	mapped	 reads.	
Interactions	 were	 called	 using	 the	 r3Cseq	 R	 package(17)	 using	 an	 aggregate	
window	of	2	kb	and	an	FDR	q-value	cut-off	of	0.05.	
	
Antibodies	
Anti-	 Epitope	 Cat.	No.	 Manufacturer	
MLL-1	 QGQESDSSETSVRGP-C	 AT71-Ab1542	 Diagenode	
MLL-1	 PIFDNFRPPPLTPED-C	 AT73-Ab1547	 Diagenode	
AF9	 SSASSPLHHEPPPPL	L-C	 AT22-Ab1327	 Diagenode	
AF9	 FTPSQTRQQGP	RSI	-C	 AT23-Ab1474	 Diagenode	
AF4	 -	 Ab31812	 Abcam	
H3K4me3	 -	 pAb003-050	 Diagenode	
H3K27ac	 -	 pAb-174-050	 Diagenode	
H3K79me2	 -	 Ab3594	 Abcam	
RUNX1	 -	 Ab23980	 Abcam	
	
Primers	
ChIP-qPCR	
Target	 Region	 Forward	 Reverse	
7	 Promoter	 A CTG GA ACGTT ACTTT	 GACAGGCCGGACTTA AC C	
9	 Promoter	 GGGA AC GA GTACAG 	 GCTCTACGATGGGGTTTGTT	
HOXA10	 Promoter	 A C CAGGAT A ACTGAAG	 TTCCCCCAGAAAACAACAAA	
EIS1	 Promoter	 C G CTAG ATT TG TC	 TCTCCCTCTTT AGTGCT	
MB	 Promoter	 GGATTGAGTCTGCCCAGG	 GATGGAAGGGCAGAGGTG	
cDNA	
Name	 Target	Region	 Forward	 Reverse	
MLL-
N1	
KMT2A	
N-terminus	
TCAGCTGCAGGGAAGAAAGG	 CTATAAACCGCCGAGGGGTC	
MLL-
N2	
KMT2A	
N-terminus	
TGTGAGAATCTTTCAGATGAGATGT	 CTTTTTCAAGGGCCAGTCGC	
MLL-C	
KMT2A	
C-terminus	
CCACAGAGTGTGGGAGGAAC	 AGAGGAACTGGATGCCAAGC	
AF9-N	
MLLT3	
N-terminus	
TGGCTAGCTCGTGTGCCGTG	 CCGGACCGCGTACGAACACC	
AF9-C	
MLLT3	
C-terminus	
GCAGCCGAAGTCGCAGAGTTA	 AGGGTGGTGGAGGTTCGTGATGT	
GAPDH	 1st	exon	 GCCTCAAGATCATCAGCAATGC	 TGGTCATGAGTCCTTCCACGA	
	 134	
Reads	from	each	library	were	parsed	bas d	 n	the	bait-specific	primer	sequence	
a d	mapped	to	 the	reduced	genom 	using	bwa	(version	0.6.2)	with	 the	default	
parameters.	4C	signal	was	calculated	 sing	a	sliding	window	of	10Kb	(±5Kb	of	a	
given	DpnII	 site)	 and	 normalized	 to	 the	 total	 number	 uniquely	mapped	 reads.	
Interaction were	 called	 using	 the	 r3Cseq	 R	 package(17)	 using	 an	 aggregate	
window	of	2	kb	and	an	FDR	q-value	cut-off	of	0.05.	
	
Antibodies	
Anti 	 Epitope	 Cat.	No.	 M nufacturer	
MLL-1	 QGQESDSSETSVRGP-C	 71 542
MLL-1	 PIFDNF PPPLTPED- 	 7 547
9 SSASSPLHHEPPPPL	L-C	 T22-Ab1327	 Diagenode	
AF9	 FTPSQTRQQGP	RSI	-C	 AT23-Ab1474	
AF4	 Ab31812	 Abcam	
4me3	 pAb003-050	 Diagenode	
H3K27ac	 pAb-174-050	 Diagenode	
H3K79me2	 -	 Ab3594	 Abcam	
RUNX1	 -	 Ab23980	 Abcam	
	
Primers	
ChIP-qPCR	
Target Region	 Forward	 Reverse	
7	 G T G AG CGT GACTT GA AGG C G CTT GACTC
HOXA9	 G GA G AGAGTACA A	 G TACG GGTT T	
HOXA10	 ACCGCAG ATGAAA T AAG	 TTCCCCCAGAAAACAACAAA	
MEIS1	 Promoter	 CGGGTTCTAGCATTCTGGTC	 TCTCCCTCTTTGCAAGTGCT	
B	 Promoter	 GGATTGAGTCTGCCCAGG	 GATGGAAGGGCAGAGGTG	
cDNA	
Name	 Target	Region	 Forward	 Reverse	
MLL-
N1	
KMT2A	
N-terminus	
TCAGCTGCAGGGAAGAAAGG	 CTATAAACCGCCGAGGGGTC	
MLL-
N2	
KMT2A	
N-ter inus	
TGTGAGAATCTTTCAGATGAGATGT	 CTTTTTCAAGGGCCAGTCGC	
MLL- 	
KMT2A	
-ter inus	
CCACAGA TGTGG AG AC	 AGAGGAACTGGATGCCAA C	
AF9-N	
MLLT3	
N-t rminus	
TGGCTAGCTCGTGTGCCGTG	 CCGGACCGCGTACGAACACC	
AF9-C	
MLLT3	
C-terminus	
GCAGCCGAAGTCGCAGAGTTA	 AGGGTGGTGGAGGTTCGTGATGT	
GAPDH	 1st	exon	 GCCTCAAGATCATCAGCAATGC	 TGGTCATGAGTCCTTCCACGA	
	 135	
4C-seq	
Name	 Reading	 Non-Reading	
PHLPP1	bait	1	 GGAAGAGGTAGTCATTTTGGA	 GGGTCCTGATGAGTCTTTGT	
PHLPP1	bait	2	 GTGGTTCTCGTAAGGGGATC	 CTCCCGGCGCATGATTAA	
BCL2	bait1	 TTTCTCGAGCTCTTGAGATC	 GGCAGGAATCCTCTTCTGAT	
BCL2	bait	2	 ATCAGGTCCTTGGAATGATC	 TGCTAGCTCTCTTCTGAAGC	
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Supplementary figures
Supplemental Figure 1: Genome wide binding of MLL and AF9. (A) The expression 
of the C-terminal and N-terminal exons of AF9 (MLLT3) in THP-1 cells and monocytes 
(left). UCSC genome browser screenshot depicting the expression of the AF9 (MLLT3) 
locus in THP-1 cells. Arrows indicate the location of primers used for rt-qPCR and the 
fusion breakpoint. (B) UCSC genome browser screenshot depicting the MEIS1 locus in 
THP-1 and MV4-11 cells. (C) Average signal intensity at MLL-AF9 target genes for MLL 
(ab1547) ChIP-seq in THP-1 cells (left), and MLL (ab1542) and AF9 (ab1474) ChIP-seq 
in patient AML_MLLAF9_5. (D) Pathway enrichment for MLL-AF9 (top) and MLL wild 
type (bottom) target genes.
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Supplemental Figure 2: Genome wide binding patterns of MLL and AF4 in MV4-
11 cells. (A) Schematic representation of MLL, AF4 and MLL-AF4. Antibody binding 
locations are indicated with dotted lines. (B) ChIP-qPCR experiments using an an-
ti-MLL-1 and an anti-AF4 antibody in MV4-11 cells with primers for HOXA7 -9, -10 
and MEIS1. (C) Classification of MLL and AF4 binding events in ‘broad’ and ‘sharp’ 
modes. Left: boxplot showing dispersion of peak lengths. Right: barplot showing ge-
nomic distributions. (D) Classification of MLL-AF4 and MLL wild type binding events. 
Average profiles showing ChIP-seq signal intensities for MLL-AF4 and MLL-wt binding 
events in MV4-11 cells. (E) Distribution of MLL-AF4 and MLL wild type binding events 
in ‘broad’ and ‘sharp’ mode. (F) Average signal of H3K27ac, H3K4me3 and H3K79me2 
at MLL-AF4 (top) and MLL wild type (middle) target genes, as compared to a random 
pool of expressed genes (bottom). (G) Pathway enrichment for MLL-AF4 (top) and MLL 
wild type (bottom) target genes. (H) Motif families on MLL-AF4 target gene promoters 
enriched over MLL wild type target gene promoters.
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MLL fusions target RUNX1 program in AML
Supplemental Figure 3: RUNX1 and CTCF binding at MLL-fusion target genes. 
(A) UCSC genome browser screenshots depicting binding of AF9, MLL, RUNX1, CTCF, 
and H3K79me2 at MLL-AF9 target genes (left) and MLL wt target genes (right). (B) 
Average signal of RUNX1 under MLL-AF4 (left) and MLL wt (right) target genes in 
MV4-11 cells.
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Supplemental Figure 4. Characterization of MLL-AF4 bound distal regulator 
elements. (A) UCSC genome browser screenshots depicting binding of AF9, MLL, 
H3K79me2, H3K4me3, and H3K27ac at MLL-AF9 target enhancers. (B) Average sig-
nal on MLL-AF4 (left) and MLL wild type (right) bound enhancers for H3K4me3 and 
H3K27ac (top), MLL and AF4 (middle), and RUNX1 and H3K79me2 (bottom). (C) Rate 
of co-occupancy of MLL-AF4 and MLL wild type bound enhancers by H3K79me2 and 
RUNX1 (top). Expression levels of MLL-AF4 and MLL wild type intergenic enhancers 
(bottom). (D) Distance to nearest TSS for MLL-AF9 bound enhancers. (E) Distance to 
nearest TSS for MLL-AF4 bound enhancers. (F) Motif family enrichment for MLL-AF4 
bound enhancers over MLL-wt bound enhancers.
Supplemental Figure 4
Re
ad
 c
ou
nt
 P
er
 M
illi
on
 m
ap
pe
d 
re
ad
s
−20000 −10000 10000 20000
Re
ad
 c
ou
nt
 P
er
 M
illi
on
 m
ap
pe
d 
re
ad
s
−20000 −10000 10000 20000
Re
ad
 c
ou
nt
 P
er
 M
illi
on
 m
ap
pe
d 
re
ad
s
−20000 −10000 10000 20000
H3K79me2
RUNX1
−20000 −10000 10000 20000
−20000 −10000 10000 20000
Genomic Region (5' −> 3')
−20000 −10000 10000 20000
H3K79me2
RUNX1
H3K79me2 RUNX1
CMLL-wt enhancersMLL-AF4 enhancers
MLL-AF4
MLL-wt
B
E
Distance to TSS (KB)
0 t
o 5
5 t
o 5
0
50
 to
 50
0
>5
00
0%
10%
20%
30%
40%
50%
60%
70%
80%
Re
gi
on
-g
en
e 
as
so
cia
tio
ns
8
102
470
107
MLL-AF4
Distance to TSS (KB)
0 t
o 5
5 t
o 5
0
50
 to
 50
0
>5
00
0%
10%
20%
30%
40%
50%
60%
70%
80%
1
172
423
33
MLL-AF9
Re
gi
on
-g
en
e 
as
so
cia
tio
ns
FD
A
0.
0
0.
1
0.
2
0.
3
0.
4
0.
5
0.
6 H3K4me3
H3K27ac
0.
0
0.
1
0.
2
0.
3
0.
4
0.
5
0.
6
H3K4me3
H3K27ac
0.
0
0.
1
0.
2
0.
3
0.
4
0.
5 MLL
AF4
0.
0
0.
1
0.
2
0.
3
0.
4
0.
5 MLL
AF4
0.
0
0.
5
1.
0
1.
5
2.
0
RP
KM
0
25
50
75
100
%
 o
f M
LL
 e
nh
an
ce
rs
PO
U
Fo
rk
he
ad
ho
m
eo
bo
x
ho
m
eo
BZ
IP
TE
AD
HM
G
GA
TA ET
S YY
C
T
F
/N
F
−I
bH
LH NR
C2
H2
T
−b
ox
A
P
−2
M
ot
if F
am
ily
 E
nr
ich
m
en
t
0.0
0.5
1.0
1.5
2.0 MLL-AF4 enhancer over MLL-wt enhancers
0.
0
0.
1
0.
2
0.
3
0.
4
0.
5
0.
0
0.
1
0.
2
0.
3
0.
4
0.
5
Start End
Start End
Start End
Start End
Start End
Start End
Genomic Region (5' −> 3')
H3K79me2 occupied enhancer
H3K79me2 occupied enhancer
H3K79me2 occupied enhancer
Scale
chr16:
100 kb hg19
54,150,000 54,200,000 54,250,000 54,300,000
RefSeq Genes
THP-1 AF9
THP-1 MLL
THP-1 H3K79me2
THP-1 H3K4me3
THP-1 H3K27ac
FTO LOC100996338 IRX3
30 _
0.5 _
10 _
0.2 _
15 _
0.25 _
100 _
1 _
100 _
1 _
Scale
chr8:
50 kb hg19
66,800,000 66,850,000 66,900,000
RefSeq Genes
THP-1 AF9
THP-1 MLL
THP-1 H3K79me2
THP-1 H3K4me3
THP-1 H3K27ac
30 _
0.5 _
10 _
0.2 _
10 _
0.25 _
100 _
1 _
100 _
1 _
Scale
chr19:
20 kb hg19
33,800,000 33,810,000 33,820,000 33,830,000 33,840,000 33,850,000 33,860,000
RefSeq Genes
THP-1 AF9
THP-1 MLL
THP-1 H3K79me2
THP-1 H3K4me3
THP-1 H3K27ac
CEBPA
CEBPA
CEBPA
CEBPA
CEBPA-AS1
30 _
0.5 _
5 _
0.2 _
10 _
0.25 _
75 _
1 _
75 _
1 _


Chapter 6
GENERAL DISCUSSION

143
General Discussion
“C”-methods: their strengths and limitationsTo characterize the long-range interaction landscape we apply a variety of different chromosome conformation capture techniques throughout this thesis. In Chapter 3 we set out to characterize the genome-wide interaction landscape in dif-
ferentiated cells before and after activation of two inducible TFs: GR and NF-kB. For this we applied ChIA-PET, a technique that allows for high-resolution genome-wide 
profiling by combining long-range interactions detection with chromatin immuno-precipitation(1). In our case, we used antibodies against RNA Polymerase II to en-
rich for promoter contacts, and GR/NF-kB co-factor P300 to enrich for enhancer contacts. While ChIA-PET is quite powerful for high-resolution interaction mapping, it also has several limitations that should be considered, e.g. interaction detection depends on the quality of the antibody and the presence of the protein of interest. To overcome this limitation in Chapter 3 we combined the protein-dependent ChIA-
PET technique with the protein-independent, locus-specific 4C-seq method(2). This 
approach allowed us to conclude that while a subset of interactions is significantly 
remodeled upon GR and NF-kB activation, these interactions are mostly established prior to treatment. 4C-seq is further used in Chapter 5 to probe the long-range in-teraction landscape of MLL-AF9 oncofusion targets in acute myeloid leukemia. This approach allowed us to identify interacting enhancers that appear to be fre-quently associated with MLL-AF9 binding. While 4C-seq is a powerful technique for long-range interaction detection, it cannot be applied to multiple loci in one experiment. Furthermore, sample comparison should be performed with caution, 
and internal biases should be taken into account, e.g. PCR amplification differenc-
es, digestion efficiency etc. In Chapter 4 we aimed to characterize the long-range interaction landscape of thousands of regulatory elements that are dynamic during monocyte-to-macrophage differentiation. Therefore we opted for the novel capture 
Hi-C (CHi-C) technique that combines the genome-wide low resolution Hi-C tech-nique with targeted enrichment by DNA hybridization, allowing for low-bias semi genome-wide interaction detection (3). 
Stimulus-induced changes in three-dimensional chroma-
tin organizationIt is well accepted that changes in chromatin organization play an important 
role in the regulation of transcription. However, the extent of the flexibility of chro-
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Chapter 6matin organization remains an open question. Studies concerning stem cell differ-entiation clearly demonstrate changes in the long-range interaction landscape, but differentiated cells are suggested to be much less plastic. In Chapter 3 we probed the 
long-range interaction landscape of fully differentiated HeLa cells in response to glu-
cocorticoids and pro-inflammatory cytokine TNFa. This stimulation activates two 
inducible TFs: GR and NF-kB. Previous studies suggested that both of these TFs bind predominantly far away from transcription start sites, and are predominantly asso-
ciated with accessible chromatin. By performing GR and NF-kB ChIP-seq analysis 
(Chapter 3), we could demonstrate that while the majority of GR and NF-kB binding 
sites are indeed located within accessible chromatin, at ~10% of sites these TFs act as pioneers (Chapter 3, Figure 1A-C), i.e. recruit co-activator P300 and remodel the chromatin landscape, in agreement with previous reports (4,5). Interestingly, these remodeled sites display increased long-range interactions frequency after treat-ment in contrast with constitutive sites (Chapter 3, Figure 3C-D). Furthermore, upon stimulation the induced sites appear to engage in multiple contacts with constitutive sites. This suggests that induced binding sites potentiate long-range interactions with and within constitutive binding sites in a P300 sub-domain, in agreement with 
a recent report on GR (6).Previous reports have suggested that the global chromatin organization is stable in 
differentiated cells (7). In agreement with this we find that only a small subset of long-range interactions respond dynamically to glucocorticoids and TNFa (Chap-ter 3). Similarly, stimulation of monocytes with b-glucan does not lead to changes 
in higher-order chromatin structure (Chapter 4). However, individual interactions 
can dynamically respond to stimulation, in agreement with a recent study on GR(8). These changes appear to be subtle, suggesting that rather than fully remodeling long-range interactions, TFs stabilize them or make them more frequent within cell populations. Future investigation is however required to discriminate between the 
two scenarios. For instance, single-cell Hi-C could help to address the question of long-range contacts heterogeneity within a given cell population. 
Chromatin organization landscape in differentiationDevelopment and differentiation is associated with the establishment of cell-
type specific gene expression programs and remodeling of the three-dimensional 
chromatin organization (reviewed in Chapter 2). In Chapter 4 we for the first time 
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General Discussionreport widespread changes in chromatin organization during monocyte-to-mac-
rophage differentiation. By profiling chromatin interactions at a set of time-points 
during differentiation, we find that higher order chromatin reorganization and epi-genetic/transcriptional remodeling are temporally uncoupled. Changes in chroma-tin organization are delayed, i.e. not detected in the Day1 Macrophage population, as compared to changes in gene expression and epigenetics (Chapter 4, Figure 1B, 3F). This uncoupling suggests that chromatin reorganization is a direct consequence of differentiation and might be independent from gene expression changes, in agree-
ment with Wijchers et al. (9). However, future experiments might be required to 
confirm this observation. Furthermore, if monocyte-to-macrophage differentiation kinetics differs between the cells in a population, this difference might also be ex-
plained by a higher sensitivity of transcriptional and epigenetic profiling, as com-
pared to Hi-C. To address this point and corroborate our finding, single-cell methods 
(RNA-seq, Hi-C) might be particularly suitable. 
Furthermore, we find that A/B compartment organization changes significantly during monocyte-to-macrophage differentiation, with the majority of regions relo-cating to the active compartment (Chapter 4, Figure 3C), likely contributing to the transcriptional plasticity of these cells (10,11). Recently, it has been shown that 
macrophage inflammatory TFs operate in an “open” chromatin environment (10), on one hand allowing for plasticity of transcriptional responses mediated by sig-nal-induced TFs, and on the other hand making these cells extremely vulnerable and prone to misregulation (12). Our data in Chapter 5 indeed suggest that the MLL oncofusions utilize a part of the “normal” myeloid program, i.e. bind to regulatory elements primed by RUNX1 and alter their activation state and epigenetic make-up. We also found that monocyte-to-macrophage differentiation is associated with strengthening of TADs and their boundaries. Interestingly, the most strengthened 
TADs were enriched for the repressive modification H3K27me3. We speculate that strengthening of these repressive TADs might be required to prevent an interaction 
of H3K27me3 with neighboring TADs. Targeted deletion of a selection of boundar-ies in macrophages could support this hypothesis and shed more light on the func-
tional significance of this remodeling for macrophage differentiation. Interestingly, a recent report utilizing genome editing to delete a TAD boundary suggested that 
insulation of a H3K27me3 region in the HoxA locus might be required to prevent the spread of active marks into the repressed domain(13). 
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Epigenetic landscape of MLLAcute myeloid leukemia is frequently associated with non-random chromo-somal translocations. In 11q23 leukemias the binding domain of lysine methylase MLL1 is fused to one of over 50 different partners (14). These MLL oncofusions in-terfere with the gene expression program via multiple mechanisms including aber-
rant transcriptional elongation(15) and H3K79me2 deposition(16). Recent studies have suggested a sensitivity of this leukemia subtype to various inhibitors of his-tone-modifying enzymes or epidrugs, thus further implicating epigenetic alterations in the MLL-induced leukemias. In Chapter 5 we characterize the transcriptional and epigenetic landscape of MLL-
AF9 and –AF4 AML in cell lines and patient blasts. We present the first genome-wide 
binding profiles for these oncofusion proteins in a human AML setting. Importantly, we show that both oncofusions bind not only at promoters but also at distal regula-
tory elements. While we find a large set of overlapping target genes, the oncofusions 
target a distinct enhancer repertoire. High-resolution 4C-seq on MLL-fusion target 
genes confirmed their interaction with MLL-fusion bound enhancers. Interestingly, 
in case of MLL-AF9, but not MLL-AF4, we detected aberrant deposition of H3K79me2 at bound enhancers. This difference can be explained by direct interaction with the 
H3K79me2 depositing DOT1L complex in case of MLL-AF9, but not –AF4(16). Sur-prisingly, we also found that a large fraction of MLL-AF9 enhancers are co-occupied by CTCF. As CTCF is known to function as an insulator and is often present at TAD boundaries, this might suggest alterations in higher order chromatin organization in AML, as has been previously demonstrated for other cancers (17,18). A follow-up 
on this observation would require a genome-wide chromatin organization profiling in an AML setting.  
Conclusions   In this thesis we aimed to address the importance of chromatin organization 
for the regulation of transcription. We showed that the inducible TFs GR and NF-kB remodel the chromatin landscape, recruit acetyltransferase P300 and enhance the long-range interactions at a subset of their binding sites. Next to that, we demon-strated that monocyte-to-macrophage differentiation is associated with changes in higher-order chromatin organization on multiple levels. Macrophages globally gain 
short-range interactions, have better-defined TAD structures, and stronger TAD 
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General Discussionboundaries. Furthermore, this differentiation is associated with an A/B compart-ment switching where the majority of switching regions is relocating to the active “A” compartment. Intriguingly, we also observed a delay in chromatin organization changes as compared to the transcriptional and epigenetic remodeling. Lastly, we characterized the epigenetic and transcriptional landscape of human MLL-induced AML. We showed that the MLL-AF9 and –AF4 oncofusions interfere with normal myeloid differentiation through several mechanisms. These include previously known mechanisms, e.g. the interaction with the DOT1L complex and interplay with RUNX1; and potential novel mechanisms, e.g. the interaction with CTCF and the en-hancer binding of the MLL-fusions. 
In summary, this thesis shows that the establishment of cell-type specific transcrip-tion programs can be associated with a dynamic remodeling of chromatin organi-zation. Furthermore, changes in chromatin organization are not exclusive for early development, but can also be triggered in differentiated cells.
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Summary
SummaryCellular specialization during development requires the establishment of cell-
type specific gene expression programs. This transcriptional remodeling is associ-ated with a dynamic regulation of chromatin accessibility, DNA methylation, histone 
modifications, etc. The three-dimensional organization of chromatin plays an im-portant role in the regulation of gene expression by controlling communication be-
tween regulatory elements. However, the extent of chromatin organization dynam-ics remains elusive. In this thesis we aimed to characterize the contribution of the long-range interac-
tion landscape to the establishment of cell-type specific and stimulus specific gene expression programs. We systematically approached this problem by focusing on chromatin interactions and their contribution to the transcriptional program in response to external stimuli in fully differentiated cells, during terminal myeloid differentiation and in a leukemic setting. In Chapter 2 we summarize and discuss the current understanding of chromatin interaction dynamics, its contribution to transcriptional regulation and its misregulation in disease. In Chapter 3 we focus on long-range interaction remodeling in fully differentiated cells upon activation of 
two transcription factors: GR and NF-kB. We show that at a small subset of their binding sites, these TFs bind to and remodel previously inaccessible chromatin. At these sites we identify dynamic remodeling of chromatin interactions upon TF ac-tivation, thus demonstrating that in fully differentiated cells, chromatin organiza-tion can be dynamically adjusted in response to a stimulus. In Chapter 4 we probe chromatin organization dynamics during monocyte-to-macrophage differentiation. 
We show that the higher-order chromatin arrangement differs significantly in these two closely related cell types. Chapter 5 focuses on the epigenetic landscape of 
MLL-AF9 and MLL–AF4 acute myeloid leukemias. We present the first genome-wide binding data of these oncofusion proteins in human AML. We show that both fusions interfere with normal myeloid development on transcriptional and epigenetic lev-els. Next to that, we demonstrate that these oncofusions do not bind exclusively to promoters, but also to distal regulatory elements. In case of MLL-AF9 this binding is associated with aberrant enhancer activation and alterations in epigenetic make-up. Furthermore, these enhancers are associated with MLL-AF9 gene targets via long-range interactions. In Chapter 6 the work presented in this thesis is summarized and discussed. 
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 SummaryAltogether, the work presented in this thesis suggests the importance of chromatin 
arrangement in the regulation of the cell-type specific transcriptional response in 
healthy and malignant cells. It demonstrates that chromatin organization is flexible and can change dynamically in response to intrinsic and extrinsic factors. 
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SamenvattingCel specialisatie tijdens de ontwikkeling vereist de opbouw van celtype spec-
ifieke genexpressie programma’s. Deze transcriptionele herinrichting gaat samen met een dynamische regulatie van chromatine toegankelijkheid, DNA methylatie, 
histon modificatie, etc. De drie dimensionale organisatie van chromatine speelt een belangrijke rol in de regulatie van genexpressie, doordat het de communicatie tus-sen andere regulerende elementen kan reguleren. De mate waarin chromatine or-ganisatie dynamisch is, is echter vooralsnog onduidelijk.Ons doel in deze thesis was het karakteriseren van de bijdrage van het lange-af-
stand-interactie-landschap aan de opbouw van celtype en stimulus specifieke gen-expressie programma’s. We benaderden dit probleem door op een systematische wijze te focussen op chromatine interacties en hun bijdrage aan het transcriptio-nele programma in respons op externe stimuli in volledig gedifferentieerde cellen, tijdens terminale myeloïde differentiatie en in een leukemische achtergrond. In 
hoofdstuk 2 vatten we de huidige kennis van de chromatine interactie dynamiek samen en bespreken de bijdrage aan transcriptionele regulatie en mis-regulatie in ziekte. In hoofdstuk 3 focussen we op het her-modelleren van lange afstand inter-acties in volledig gedifferentieerde cellen na activatie van twee transcriptie factoren: 
GR en NF-κB. We laten zien dat, op een klein deel van hun bindingsplaatsen, deze twee transcriptie factoren aan vooralsnog ontoegankelijk chromatine binden en het 
her-modelleren. Op deze bindingsplaatsen identificeerden we ook het dynamisch her-modelleren van chromatine interacties na TF-activatie, waarmee we laten zien dat in volledig gedifferentieerde cellen chromatine interacties dynamisch kunnen worden aangepast in antwoord op een stimulus. In hoofdstuk 4 bekijken we de chromatine interactie dynamiek tijdens monocyt naar macrofaag differentiatie. We 
laten zien dat de hogere orde chromatine verdeling significant verschilt in deze twee zeer gerelateerde cel types. Hoofdstuk 5 gaat in op het epi-genetische land-schap van MLL-AF9 en MLL-AF4 acute myeloïde leukemieën. We presenteren de eerste genoom-wijde bindings data van deze onco-fusie eiwitten in humane AML. We laten zien dat beide fusies interfereren met normale myeloïde ontwikkeling op een transcriptioneel en epi-genetisch niveau. Daarnaast laten we zien dat deze on-co-fusies niet alleen maar aan promotors binden, maar ook aan distale reguleren-de elementen (versterkers). In het geval van MLL-AF9 is deze binding geassocieerd met afwijkende versterker activatie en veranderingen in epi-genetische opmaak. We 
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Samenvattinglaten ook zien dat deze versterkers geassocieerd zijn met MLL-AF9 doelwit genen via lange afstand interacties. In hoofdstuk 6 vatten we het werk dat in deze thesis wordt gepresenteerd samen en bespreken het.Samengenomen suggereert het werk dat we in deze thesis presenteren de belan-
grijkheid van chromatine indeling voor de regulatie van de celtype specifieke tran-
scriptionele respons in gezonde en zieke cellen. Het laat zien dat de chromatine 
organisatie flexibel is en dynamisch kan veranderen in respons op intrinsieke en extrinsieke factoren.
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